US20090214618A1 - Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications - Google Patents
Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications Download PDFInfo
- Publication number
- US20090214618A1 US20090214618A1 US11/887,041 US88704106A US2009214618A1 US 20090214618 A1 US20090214618 A1 US 20090214618A1 US 88704106 A US88704106 A US 88704106A US 2009214618 A1 US2009214618 A1 US 2009214618A1
- Authority
- US
- United States
- Prior art keywords
- nitric oxide
- group
- particle
- releasing
- releasing particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C=N*CC=C*CCC*=N Chemical compound C=N*CC=C*CCC*=N 0.000 description 2
- TXUGVACWGVLQQS-UHFFFAOYSA-N C.C.N=O.N=O.OOO.OOO Chemical compound C.C.N=O.N=O.OOO.OOO TXUGVACWGVLQQS-UHFFFAOYSA-N 0.000 description 1
- ZYPUDZBCVGDAAM-UHFFFAOYSA-N C1CCOC1.CC(=O)Cl.CCN(CC)CC.CN.CNC.CNC(C)=O.[AlH3].[LiH] Chemical compound C1CCOC1.CC(=O)Cl.CCN(CC)CC.CN.CNC.CNC(C)=O.[AlH3].[LiH] ZYPUDZBCVGDAAM-UHFFFAOYSA-N 0.000 description 1
- MIQVFZQWJVJTHO-UHFFFAOYSA-N C1CCOC1.CCCCCCC(=O)Cl.CCCCCCC(=O)NC.CCCCCCCNC.CCN(CC)CC.CN.[AlH3].[LiH] Chemical compound C1CCOC1.CCCCCCC(=O)Cl.CCCCCCC(=O)NC.CCCCCCCNC.CCN(CC)CC.CN.[AlH3].[LiH] MIQVFZQWJVJTHO-UHFFFAOYSA-N 0.000 description 1
- RXBUKRRSNZRNTR-UHFFFAOYSA-N CC(=O)CC(C)=O.CCN(CC)CC.CN.CNC(C)=O.CO Chemical compound CC(=O)CC(C)=O.CCN(CC)CC.CN.CNC(C)=O.CO RXBUKRRSNZRNTR-UHFFFAOYSA-N 0.000 description 1
- MVZVDAGWAAZJPE-UHFFFAOYSA-N CC1=CC=C(C)C=C1.CC1=CC=CC(C)=C1.CC1=CC=CC=C1C Chemical compound CC1=CC=C(C)C=C1.CC1=CC=CC(C)=C1.CC1=CC=CC=C1C MVZVDAGWAAZJPE-UHFFFAOYSA-N 0.000 description 1
- MXEIXINMXIYCPN-WSELPHFCSA-M CCCCCCCN(C)/N([O-])=C/[O-].CCCCCCCNC.[Na+] Chemical compound CCCCCCCN(C)/N([O-])=C/[O-].CCCCCCCNC.[Na+] MXEIXINMXIYCPN-WSELPHFCSA-M 0.000 description 1
- FQEPEPPSWJOMEK-UHFFFAOYSA-N CN.CNC(=O)C1CCCN1 Chemical compound CN.CNC(=O)C1CCCN1 FQEPEPPSWJOMEK-UHFFFAOYSA-N 0.000 description 1
- NYOAQASPJNBHFQ-UHFFFAOYSA-N CO[Si](CCC=[N]=CCCCCCN)(OC)OC Chemical compound CO[Si](CCC=[N]=CCCCCCN)(OC)OC NYOAQASPJNBHFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
Definitions
- the interior region further comprises an organic linker selected from the group consisting of a labile linker responsive to changes in pH, a labile linker sensitive to electromagnetic radiation, a labile linker susceptible to degradation by enzymatic action, a hydrophobic linker, an amphiphilic linker, and combinations thereof.
- an organic linker selected from the group consisting of a labile linker responsive to changes in pH, a labile linker sensitive to electromagnetic radiation, a labile linker susceptible to degradation by enzymatic action, a hydrophobic linker, an amphiphilic linker, and combinations thereof.
- the NO donor is selected from the group consisting of a diazeniumdiolate, a nitrosamine, a hydroxylamine, a nitrosothiol, a hydroxylamine, and a hydroxyurea.
- the NO donor is covalently bound to one of the interior region, the exterior region, the core, or to combinations thereof.
- the NO donor is encapsulated in one of the interior region, the exterior region, the core, or to combinations thereof.
- the NO donor is associated with part of the particle via a non-covalent interaction selected from the group consisting of Van der Waals interactions, electrostatic forces, hydrogen bonding, or combinations thereof.
- the organic linker comprises a functional group capable of conferring an on/off state of nitric oxide release to the nitric oxide-releasing particle, wherein the functional group is selected from the group consisting of an ester, a hydrazone, an acetal, a thiopropionate, a photolabile moiety, and an amino acid sequence subject to enzymatic degradation.
- the NO-releasing particle has a diameter of from between about 1 nm and about 1000 nm. In some embodiments, the particle has a metallic cluster core and the diameter of the particle is from between about 1 nm and about 5 nm. In some embodiments the particle has a co-condensed silica network core and has a diameter of between about 2 nm and about 10 ⁇ m.
- the presently disclosed subject matter provides a method or a formulation for delivering nitric oxide to a subject.
- the method comprises administering an effective amount of a NO-releasing particle to the subject, said particle comprising a NO donor, an exterior region, and an interior region having a volume, the volume of the interior region at least partially filled by a core selected from:
- FIG. 1 is a schematic representation of a nitric oxide (NO)-releasing particle comprising a core CR, an interior region IR, a linker LK having a labile portion LP, a nitric oxide (NO) donor NO and an exterior EP.
- NO nitric oxide
- FIG. 2 is a synthesis scheme for preparing the presently disclosed NO-releasing monolayer protected cluster (MPC) gold nanoparticles.
- FIG. 5A is a schematic representation of the synthesis of NO-releasing co-condensed silica particles using a “post-charging” method, wherein amino groups from aminoalkoxysilanes are reacted with NO gas after co-condensation in a silica network.
- FIG. 5B is a schematic representation of the synthesis of NO-releasing co-condensed silica particles using a “pre-charging” method, wherein aminoalkoxysilanes are reacted with NO gas prior to co-condensation to form a silica network.
- FIG. 6A is the structure of N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3).
- FIG. 6B is the structure of (aminoethylaminomethyl)phenethyltrimethoxysilane (AEMP3).
- FIG. 9B shows the structure of TECOFLEX® polyurethane, wherein n and n′ are integers.
- FIG. 13 is a plot showing nitric oxide release profiles from monolayer protected cluster (MPC) gold nanoparticles derivatized with various diamines.
- Line a is the nitric oxide release profile of underivatized MPC gold nanoparticles.
- Line b is the nitric oxide release profile from MPC gold nanoparticles derivatized with 14% ethylenediamine.
- Line c shows the nitric oxide release profile from MPC gold nanoparticles derivatized with 21% ethylenediamine.
- Line d shows the nitric oxide release profile from MPC gold nanoparticles derivatized with 21% ethylenediamine.
- Line e shows the nitric oxide release profile from MPC gold nanoparticles derivatized with 21% diethylenetriamine.
- Line f shows the nitric oxide release profile from MPC gold nanoparticles derivatized with 21% hexanediamine.
- FIG. 14 is a schematic representation showing the release of nitric oxide from functionalized monolayer protected cluster (MPC) gold nanoparticles.
- FIG. 15 is a schematic representation of the chemical structure of polypropylenimine hexadecaamine dendrimer (DAB-Am-16).
- FIG. 21C is a plot of % surface coverage of co-condensed amine ligands versus AEAP3 content loaded during the synthesis of AEAP3-modified silica composites.
- FIG. 27 is a graph showing the cytotoxicity of control (dark squares) and NO-releasing MAP3 co-condensed (open squares) silica nanoparticles on normal (T29, immortalized) cells as well as the cytotoxicity of control (dark circles) and NO-releasing MAP3 co-condensed (open circles) silica nanoparticles on tumor (A2780) cells.
- FIG. 30A is a photograph showing colonies of P. aeruginosa that formed on nutrient agar plates after incubation with sterile phosphate buffered solution (PBS) at 37° C.
- PBS sterile phosphate buffered solution
- cancers include, but are not limited to, skin cancers, connective tissue cancers, adipose cancers, breast cancers, lung cancers, stomach cancers, pancreatic cancers, ovarian cancers, cervical cancers, uterine cancers, anogenital cancers, kidney cancers, bladder cancers, colon cancers, prostate cancers, central nervous system (CNS) cancers, retinal cancer, blood, and lymphoid cancers.
- skin cancers connective tissue cancers, adipose cancers, breast cancers, lung cancers, stomach cancers, pancreatic cancers, ovarian cancers, cervical cancers, uterine cancers, anogenital cancers, kidney cancers, bladder cancers, colon cancers, prostate cancers, central nervous system (CNS) cancers, retinal cancer, blood, and lymphoid cancers.
- connective tissue cancers include, but are not limited to, connective tissue cancers, adipose cancers, breast cancers, lung cancers, stomach cancers, pancreatic
- semiconductor nanocrystal and “quantum dot” are used interchangeably herein to refer to semiconductor nanoparticles comprising an inorganic crystalline material that is luminescent (i.e., that is capable of emitting electromagnetic radiation upon excitation), and including an inner core of one or more first semiconductor materials that is optionally contained within an overcoating or “shell” of a second semiconductor material.
- a semiconductor nanocrystal core surrounded by a semiconductor shell is referred to as a “core/shell” semiconductor nanocrystal.
- the surrounding shell material can optionally have a bandgap energy that is larger than the bandgap energy of the core material and can be chosen to have an atomic spacing close to that of the core substrate.
- Suitable semiconductor materials for the core and/or shell include, but are not limited to, materials comprising a first element selected from Groups 2 and 12 of the Periodic Table of the Elements and a second element selected from Group 16. Such materials include, but are not limited to ZnS, ZnSe, ZnTe, CDs, CdSe, CdTe, HgS, HgSe, HgTe, MgS, MgSe, MgTe, CaS, CaSe, CaTe, SrS, SrSe, SrTe, BaS, BaSe, BaTe, and the like. Suitable semiconductor materials also include materials comprising a first element selected from Group 13 of the Periodic Table of the Elements and a second element selected from Group 15.
- nitric oxide releasing or “nitric oxide donating” refer to methods of donating, releasing and/or directly or indirectly transferring any of the three redox forms of nitrogen monoxide (NO + , NO ⁇ , NO). In some cases, the nitric oxide releasing or donating is accomplished such that the biological activity of the nitrogen monoxide species is expressed at the intended site of action.
- alkyl refers to C 1-20 inclusive, linear (i.e., “straight-chain”), branched, or cyclic, saturated or at least partially and in some cases fully unsaturated (i.e., alkenyl and alkynyl)hydrocarbon chains, including for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and allenyl groups.
- “Higher alkyl” refers to an alkyl group having about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms.
- “alkyl” refers, in particular, to C 1-8 straight-chain alkyls. In other embodiments, “alkyl” refers, in particular, to C 1-8 branched-chain alkyls.
- aryl means a cyclic aromatic comprising about 5 to about 10 carbon atoms, e.g., 5, 6, 7, 8, 9, or 10 carbon atoms, and including 5- and 6-membered hydrocarbon and heterocyclic aromatic rings.
- cyclic alkyl chain There can be optionally inserted along the cyclic alkyl chain one or more oxygen, sulfur or substituted or unsubstituted nitrogen atoms, wherein the nitrogen substituent is hydrogen, alkyl, substituted alkyl, aryl, or substituted aryl, thus providing a heterocyclic group.
- Representative monocyclic cycloalkyl rings include cyclopentyl, cyclohexyl, and cycloheptyl.
- Multicyclic cycloalkyl rings include adamantyl, octahydronaphthyl, decalin, camphor, camphane, and noradamantyl.
- carbonyl refers to the —(C ⁇ O)— group.
- halo refers to fluoro, chloro, bromo, and iodo groups.
- the NO releasing moiety or NO donor is engineered in such a fashion as not to disrupt the other particle descriptors while storing its quantity of NO until the appropriate targeting of the particle has occurred.
- the NO release can be initiated thermally or via any of the degradation strategies for the labile portion of the linker as described herein below.
- the NO donor can be any moiety capable of releasing NO, including N-diazeniumdiolates, nitrosamines, hydroxyl nitrosamines, nitrosothiols, hydroxylamines, hydroxyureas, metal complexes, organic nitrites and organic nitrates. See, Wang, P.
- NO-releasing MPC gold nanoparticles provides for a range of biomedical and pharmaceutical applications including in vivo sensor design and topical creams to enhance wound healing and/or dilate blood vessels below the skin.
- Inorganic-organic hybrid silica nanoparticles functionalized ceramic composites prepared from silicon dioxide, have been explored for applications spanning separation, biological labeling, diagnostics, and carrier systems for the controlled delivery of drugs, genes, and proteins. See Lai, C.-Y., et al., J. Am. Chem. Soc., 125, 4451-4459 (2003); Munoz, B., et al., Chem. Mater., 15, 500-503 (2003); Roy, I., et al., Proc. Natl. Acad. Sci, U.S.A., 102, 279-284 (2005); Trewyn, B. G., et al., Nano.
- the alkoxysilane is a tetraalkoxysilane having the formula Si(OR) 4 , wherein R is an alkyl group.
- R is an alkyl group.
- the R groups can be the same or different.
- the tetraalkoxysilane is selected tetramethyl orthosilicate (TMOS) or tetraethyl orthosilicate (TEOS).
- the aminoalkoxysilane can be selected from N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP3); N-(6-aminoethyl)aminopropyltrimethoxysilane; (3-trimethoxysilylpropyl)di-ethylenetriamine (DET3); (aminoethylaminomethyl)phenethyltrimethoxysilane (AEMP3); [3-(methylamino)propyl]trimethoxysilane; N-butylamino-propyltrimethoxysilane; N-ethylaminoisobutyltrimethoxysilane; N-phenylamino-propyltrimethoxysilane; and N-cyclohexylaminopropyltrimethoxysilane.
- the structures of representative suitable aminoalkoxysilanes are shown in FIG. 6 .
- the co-condensed silica network comprises (i.e., is formed from the condensation of a solution containing) between about 10 mol % to about 99 mol % of tetraalkoxysilane; about 1 mol % to about 90 mol % of aminoalkoxysilane; about 0 mol % to about 20 mol % of fluorinated silane; about 0 mol % to about 20 mol % of cationic or anionic silane; and about 0 mol % to about 20 mol % of alkylsilane.
- FIG. 7 shows the schematic representation of the synthesis of a mesoporous silica network using micelles as pore templates.
- micelles can self-associate in a controlled solvent environment to form an ordered three-dimensional structure, such as a micellular rod, or an even more highly structured array of multiple rods.
- Solutions containing mixtures of silanes can be introduced into the micelle solution and condensed, surrounding, but not penetrating, the micelle rods. Following condensation of the silane mixture, the micelles can be removed from the condensed silica via solvent extraction, leaving behind pores in the silica.
- the presently disclosed silica chemistry is combined with hydroxylamine chemistry. In some embodiments, the presently disclosed silica chemistry is combined with hydroxyurea chemistry.
- Controlled and/or targeted delivery techniques typically enhance the efficacy and/or safety of an active agent by controlling the rate and/or location of the release of the active agent.
- the release of nitric oxide from the presently disclosed nitric oxide-releasing particles can be selectively turned on or turned off (i.e., triggered), as desired.
- a labile group LP at position C can be degraded more quickly by environmental conditions to which particle P is subjected, in turn exposing NO donor NO located in interior IR of particle P to the same environmental conditions sooner.
- Labile groups LP located more deeply in particle interior IR at positions A or B can, in some embodiments, provide for prolonged or delayed release kinetics.
- the organic linker is a hydrophobic linker.
- a hydrophobic linker can be choosen as an approach for protecting the NO donor, for example the diazeniumdiolate, and/or the labile linker from contact with water or protons when the particle is placed in an aqueous environment.
- the length and exact chemical composition of a hydrophobic linker can, therefore, be used to control the NO-release kinetics.
- the term hydrophobic can include groups that are strongly hydrophobic (i.e., have a very low dielectric constant) or are only somewhat hydrophobic (i.e., would allow water to slowly penetrate into the interior of the particle).
- the exterior can comprise a polymeric layer, for example a hydrophilic polymer to impart improved aqueous solutility or a known biocompatible polymer.
- the polymeric layer can be a biodegradable polymer, which can protect the NO donor from water for a period of time when used either in vivo or in vitro. Such a polymer coating can thereby affect the NO-release kinetics by allowing for continued NO-release over time as the polymer coating degrades.
- Suitable polymers for functionalizing the exterior of the presently described particles include (poly)ethyleneoxide, (poly)urethanes, N-(2-hydroxypropyl)methacrylamide copolymes, and lactide/glycolide copolymers (e.g. PLGA).
- additional funcitonalization of the particle enables targeting of specific cells, tissues, or organs.
- the presently disclosed nitric oxide-releasing particles can be further modified by attaching selective recognition agents to the surface or exterior thereof.
- selective recognition agents include, but are not limited to small molecule ligands; biomolecules, such as antibodies and antibody fragments; and other agents such as cytokines, hormones, carbohydrates, sugars, vitamins, and peptides.
- a specific targeting moiety is not required in all cases.
- the site specific targeting can also include a more passive approach, such as the enhanced permeability and retention effect (EPR) associated with tumor vasculature.
- EPR enhanced permeability and retention effect
- Site specific targeting can also be accomplished by the used of NO-release particles containing linkers that trigger release of the nitric oxide only upon contact with enzymes specific to a disease state or to a particular organ or tissue.
- targeting can be accomplished via localized delivery of the particles, for example, topically directly to a wound, or through injection directly to a tumor site.
- the targeting moiety can be designed around a tumor suppressor, a cytokine, a chemokine, a tumor specific receptor ligand, a receptor, an inducer of apoptosis, or a differentiating agent.
- the targeting moiety can be developed to target a factor associated with angiogenisis.
- the targeting moiety can be designed to interact with known angiogenisis factors such as vascular endothelial growth factor (VEGF). See Brannon-Peppas, L. and Blanchette, J. O., Advanced Drug Delivery Reviews, 56, 1649-1659 (2004).
- VEGF vascular endothelial growth factor
- Cytokines that can be targeted by the presently disclosed particles include, but are not limited to, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, ILA 1, IL-12, IL-13, IL-14, IL-15, TNF, GM-CSF, ⁇ -interferon and ⁇ -interferon.
- Chemokines that can be used include, but are not limited to, M1P1 ⁇ , M1P1 ⁇ , and RANTES.
- Enzymes that can be targeted include, but are not limited to, cytosine deaminase, hypoxanthine-guanine phosphoribosyltransferase, galactose-1-phosphate uridyltransferase, phenylalanine hydroxylase, glucocerbrosidase, sphingomyelinase, ⁇ -L-iduronidase, glucose-6-phosphate dehydrogenase, HSV thymidine kinase, and human thymidine kinase.
- the ability of a particle to provide targeted delivery of NO is not limited to embodiments involving pendant targeting agents attached to the particle exterior.
- Non exterior-associated characteristics of the particle also can be used for targeting.
- the enhanced permeability and retention (EPR) effect is used in targeting.
- the EPR effect is the selective concentration of macromolecules and small particles in the tumor microenvironment, caused by the hyperpermeable vasculature and poor lymphatic drainage of tumors.
- the exterior of the particle can be coated with or conjugated to a hydrophilic polymer to enhance the circulation half-life of the particle and to discourage the attachement of plasma proteins to the particle.
- the presently disclosed therapeutic compositions comprise an additional therapeutic agent in combination with the nitric oxide-releasing nanoparticles, wherein the additional therapeutic agent has additional desired therapeutic properties or enhances the therapeutic properties of the nitric oxide-releasing nanoparticles.
- the additional therapeutic agent can be administered in the same or a different therapeutic composition.
- the term “in combination” can refer to the administration of active agents in a single composition or in one or more separate compositions.
- the compounds also can be formulated as a preparation for implantation or injection.
- the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives (e.g., as a sparingly soluble salt).
- suitable polymeric or hydrophobic materials e.g., as an emulsion in an acceptable oil
- ion exchange resins e.g., as sparingly soluble derivatives (e.g., as a sparingly soluble salt).
- the compounds also can be formulated in rectal compositions (e.g., suppositories or retention enemas containing conventional suppository bases, such as cocoa butter or other glycerides), creams or lotions, or transdermal patches.
- an effective amount is used herein to refer to an amount of the therapeutic composition (e.g., a composition comprising a nitric oxide-releasing particle) sufficient to produce a measurable biological response.
- Actual dosage levels of active ingredients in an active composition of the presently disclosed subject matter can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired response for a particular subject and/or application.
- the selected dosage level will depend upon a variety of factors including the activity of the composition, formulation, the route of administration, combination with other drugs or treatments, severity of the condition being treated, and the physical condition and prior medical history of the subject being treated.
- a minimal dose is administered, and dose is escalated in the absence of dose-limiting toxicity to a minimally effective amount. Determination and adjustment of an effective dose, as well as evaluation of when and how to make such adjustments, are known to those of ordinary skill in the art of medicine.
- the NO-releasing particles can be incorporated into polymeric films. Such incorporation can be through physically embedding the particles into polymer surfaces, via electrostatic association of particles onto polymeric surfaces, or by covalent attachment of particles onto reactive groups on the surface of a polymer. Alternatively, the particles can be mixed into a solution of liquid polymer precursor, becoming entrapped in the polymer matrix when the polymer is cured. Polymerizable groups can also be used to functionalize the exterior of the particles, whereupon, the particles can be co-polymerized into a polymer during the polymerization process.
- DAB-C7-64 was charged at 5-atm nitric oxide for three days in the presence of NaOMe/MeOH. This procedure yielded 45 moles NO/mole dendrimer (35.6% conversion) and 1.48 ⁇ 10 ⁇ 7 moles NO released.
- DAB-Ac-16 (Scheme 6) was charged at 5-atm nitric oxide for three days in the presence of NaOMe. This procedure yielded 0.039 moles NO/mole dendrimer (0.12% conversion) and 4.95 ⁇ 10 ⁇ 10 moles NO released.
- DAB-Pro-16 (Scheme 7) was charged at 5-atm nitric oxide for three days in the presence of NaOMe. This procedure yielded 42 moles NO/mole dendrimer (130% conversion) and 1.92 ⁇ 10 ⁇ 7 moles NO released.
- NO-releasing silica particles with a particle size ranging from about 200 nm to about 300 nm are prepared following the method described by Zhang, H., et al., J. Am. Chem. Soc., 125, 5015 (2003).
- Tetraethyl orthosilicate (TEOS), tetramethylsilane (TMS), and sodium methoxide (NaOMe) were purchased from Fluka (Buchs, Switzerland).
- Silanes including (aminoethylaminomethyl)phenethyltrimeth-oxysilane (AEMP3), N-(6-aminohexyl)aminopropyltrimethoxysilane (AHAP3), N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3), and N-[3-(trimeth-oxysilyl)propyl]diethylenetriamine (DET3) were purchased from Gelest (Tullytown, Pa., United States of America).
- the size of silica nanoparticles was tunable by varying the type and concentration of aminoalkoxysilane used.
- Contact mode atomic force microscope (AFM) images of silica spheres having different silane compositions are shown in FIGS. 20A-20E .
- the diameter of control (TEOS only) silica particles was 250 ⁇ 20 nm.
- Altering the TEOS solution to include 10 mol % AHAP3 decreased the diameter of the particles to 20 ⁇ 2 nm.
- NO release characteristics including the total amount of NO (t[NO]), half-life of NO release (t 1/2 ), maximum flux of NO release ([NO] m ), and time necessary (t m ) to reach [NO] m were evaluated as a function of aminoalkoxysilane structure and amount. The results are summarized in Table 4, below.
- A2780 ovarian epithelial tumor cells were treated with varying doses of control and NO-releasing AHAP3 silica (0.013-1.0 mg/mL) for 48 h.
- the viability of the A2780 cells was reduced upon exposure to NO-releasing AHAP3 silica at low doses, and the proliferation of A2780 cells was almost completely inhibited by NO-releasing AHAP3 silica at a dose of 0.50 mg/mL [minimum inhibitory concentration (MIC) at ⁇ 5% survival; corresponding to 0.75 mM of NO].
- the IC 50 dose (50% inhibitory concentration) of NO donor AHAP3 silica was 0.02 mg/mL (0.03 mM NO).
- the inhibitory concentrations of the NO-releasing silica proved to be significantly lower than those of small molecule NO donors (e.g., MIC and IC 50 for PYRRO/NO were 4.4 and 2 mM NO, respectively).
- control electrodes were also prepared: a control sensor having only a protecting layer and a GOx layer, and a sensor containing all four layers only prepared with silica nanoparticles that did not contain NO-donors.
- the sensitivity of the various sensors was evaluated in PBS (0.05 M, pH 7.4) using an applied potential of +7 V vs. Ag/AgCl.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/887,041 US20090214618A1 (en) | 2005-05-27 | 2006-05-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68557805P | 2005-05-27 | 2005-05-27 | |
US11/887,041 US20090214618A1 (en) | 2005-05-27 | 2006-05-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
PCT/US2006/020781 WO2006128121A2 (fr) | 2005-05-27 | 2006-05-30 | Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/020781 A-371-Of-International WO2006128121A2 (fr) | 2005-05-27 | 2006-05-30 | Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/157,036 Continuation US11691995B2 (en) | 2005-05-27 | 2011-06-09 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090214618A1 true US20090214618A1 (en) | 2009-08-27 |
Family
ID=37452970
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/887,041 Abandoned US20090214618A1 (en) | 2005-05-27 | 2006-05-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US13/157,036 Active 2028-06-06 US11691995B2 (en) | 2005-05-27 | 2011-06-09 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US13/168,597 Active US8282967B2 (en) | 2005-05-27 | 2011-06-24 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/015,015 Active US8962029B2 (en) | 2005-05-27 | 2013-08-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/014,939 Active US8956658B2 (en) | 2005-05-27 | 2013-08-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/573,099 Active US9403851B2 (en) | 2005-05-27 | 2014-12-17 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/611,574 Active US9403852B2 (en) | 2005-05-27 | 2015-02-02 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/157,036 Active 2028-06-06 US11691995B2 (en) | 2005-05-27 | 2011-06-09 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US13/168,597 Active US8282967B2 (en) | 2005-05-27 | 2011-06-24 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/015,015 Active US8962029B2 (en) | 2005-05-27 | 2013-08-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/014,939 Active US8956658B2 (en) | 2005-05-27 | 2013-08-30 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/573,099 Active US9403851B2 (en) | 2005-05-27 | 2014-12-17 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US14/611,574 Active US9403852B2 (en) | 2005-05-27 | 2015-02-02 | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
Country Status (7)
Country | Link |
---|---|
US (7) | US20090214618A1 (fr) |
EP (3) | EP3556401A1 (fr) |
JP (3) | JP5274248B2 (fr) |
AU (1) | AU2006249323B2 (fr) |
CA (2) | CA2912259C (fr) |
ES (1) | ES2731298T3 (fr) |
WO (1) | WO2006128121A2 (fr) |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090069884A1 (en) * | 2007-09-06 | 2009-03-12 | Biotronik Vi Patent Ag | Stent having a base body of a biocorrodable alloy |
US20090092843A1 (en) * | 2005-05-19 | 2009-04-09 | Joachim Arlt | Process for modifying a silicone rubber surface |
US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
US20090112193A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
US20090191284A1 (en) * | 2006-07-26 | 2009-07-30 | Stmicroelectronics S.R.I. | Use of nitroaniline derivatives for the production of nitric oxide |
US20100297200A1 (en) * | 2007-10-12 | 2010-11-25 | The University Of North Carolina Atchapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
US20100323036A1 (en) * | 2009-06-22 | 2010-12-23 | Geno Llc | Nitric Oxide Therapies |
WO2011022680A2 (fr) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Pansements, procédés d'utilisation de ceux-ci et procédés de formation de ceux-ci |
WO2011022652A1 (fr) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Gels topiques |
US20110166536A1 (en) * | 2007-10-30 | 2011-07-07 | Hyde Roderick A | Substrates for nitric oxide releasing devices |
US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
WO2012082976A1 (fr) | 2010-12-15 | 2012-06-21 | Novan, Inc. | Procédés de diminution de la production de sébum dans la peau |
US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
WO2012118819A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8349262B2 (en) | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
WO2013006608A1 (fr) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Compositions topiques |
WO2013029009A1 (fr) | 2011-08-24 | 2013-02-28 | Novan, Inc. | Macromolécules libérant de l'oxyde nitrique ajustables possédant plusieurs structures donneuses d'oxyde nitrique |
US20130082368A1 (en) * | 2011-09-30 | 2013-04-04 | Samsung Electronics Co., Ltd. | Emi shielded semiconductor package and emi shielded substrate module |
WO2013063354A1 (fr) * | 2011-10-27 | 2013-05-02 | Novan, Inc. | Compositions pour bain libérant de l'oxyde nitrique et leurs procédés d'utilisation |
WO2013138075A1 (fr) | 2012-03-14 | 2013-09-19 | Novan, Inc. | Compositions pharmaceutiques libérant de l'oxyde nitrique |
US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20140065200A1 (en) * | 2012-08-28 | 2014-03-06 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing nanorods and their methods of use |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US8937143B2 (en) | 2011-01-20 | 2015-01-20 | Novan, Inc. | Temperature controlled sol-gel co-condensation |
US20150125398A1 (en) * | 2012-05-11 | 2015-05-07 | University Of Iowa Research Foundation | Multimodal imaging methods using mesoporous silica nanoparticles |
US9042765B2 (en) | 2012-01-16 | 2015-05-26 | Samsung Electronics Co., Ltd. | Image forming apparatus with improved heat transmission |
WO2015021382A3 (fr) * | 2013-08-08 | 2015-11-05 | Novan, Inc. | Compositions topiques et procédés d'utilisation de celles-ci |
WO2016007834A1 (fr) | 2014-07-11 | 2016-01-14 | Novan, Inc. | Compositions antivirales topiques et méthodes d'utilisation de celles-ci |
US9427605B2 (en) | 2005-03-24 | 2016-08-30 | Novan, Inc. | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
WO2017079268A1 (fr) * | 2015-11-02 | 2017-05-11 | University Of North Carolina- Chapel Hill | Silice mésoporeuse fonctionnalisée par une réaction d'échange d'ions tensioactifs de type aminosilane : conception régulée d'échafaudage et libération d'oxyde nitrique |
US9757397B2 (en) | 2011-07-05 | 2017-09-12 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for the same |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
WO2018067838A1 (fr) * | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | Polyesters hyperramifiés médiés par un s-nitrosothiol |
CN108414655A (zh) * | 2018-05-28 | 2018-08-17 | 陕西师范大学 | 一种磁性超支化聚酰胺-胺及在有机磷农药残留检测中的应用 |
US20190039910A1 (en) * | 2017-08-01 | 2019-02-07 | University Of Georgia Research Foundation, Inc. | Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof |
US10206947B2 (en) | 2013-08-08 | 2019-02-19 | Novan, Inc. | Topical compositions and methods of using the same |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
US10416167B2 (en) | 2012-02-17 | 2019-09-17 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
WO2019201195A1 (fr) | 2018-04-16 | 2019-10-24 | 上海岸阔医药科技有限公司 | Méthode pour prévenir ou traiter les effets secondaires d'une cancérothérapie |
CN110461338A (zh) * | 2017-03-28 | 2019-11-15 | 北卡罗来纳大学查佩尔希尔分校 | 作为可生物降解抗菌支架的释放一氧化氮的聚氨基糖苷类和其制备方法 |
US10582711B2 (en) * | 2015-09-25 | 2020-03-10 | Leader Optronics Technology Co., Ltd. | Method for imparting to an article or product antimicrobial activity and the article or product having the antimicrobial activity |
WO2020180705A1 (fr) * | 2019-03-01 | 2020-09-10 | The University Of North Carolina At Chapel Hill | Polymères étendus libérant de l'oxyde nitrique par l'intermédiaire de nanoparticules de silice mésoporeuse fonctionnalisées |
US10849864B2 (en) | 2015-07-28 | 2020-12-01 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
US10912743B2 (en) | 2016-03-02 | 2021-02-09 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
US10925689B2 (en) | 2014-07-14 | 2021-02-23 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
US11026965B2 (en) | 2018-03-06 | 2021-06-08 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11072668B2 (en) | 2017-01-03 | 2021-07-27 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11166980B2 (en) | 2016-04-13 | 2021-11-09 | Novan, Inc. | Compositions, systems, kits, and methods for treating an infection |
WO2022015840A3 (fr) * | 2020-07-16 | 2022-02-10 | University Of Georgia Research Foundation, Inc. | Substrats polymères antimicrobiens de qualité médicale présentant des propriétés antifongiques et antibactériennes |
US11285171B2 (en) * | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
CN114630661A (zh) * | 2019-11-05 | 2022-06-14 | 佐治亚大学研究基金会股份有限公司 | 功能改性的美登木素生物碱及其组合物和使用方法 |
US11421044B2 (en) | 2018-12-28 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
US11534382B2 (en) | 2017-06-19 | 2022-12-27 | Novan, Inc. | Topical compositions and methods of using the same |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007521118A (ja) | 2004-01-07 | 2007-08-02 | ノクシライザー,インコーポレイテッド | 殺菌システムおよび装置 |
US8017074B2 (en) | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
EP1718603A4 (fr) | 2004-02-09 | 2009-09-23 | Noxilizer Inc | Molecules liberant du monoxyde d'azote |
US7699823B2 (en) | 2005-09-07 | 2010-04-20 | Tyco Healthcare Group Lp | Wound dressing with vacuum reservoir |
DE112008001301T5 (de) | 2007-05-14 | 2010-04-29 | Reserach Foundation Of State University Of New York | Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm |
CA2700172A1 (fr) * | 2007-09-21 | 2009-03-26 | Enox Biopharma, Inc. | Tubes antimicrobiens liberant un gaz pour drainer l'oreille |
US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
WO2009131931A1 (fr) * | 2008-04-21 | 2009-10-29 | 3M Innovative Properties Company | Compositions libérant de l’oxyde nitrique, dispositifs et procédés |
GB0810359D0 (en) | 2008-06-06 | 2008-07-09 | Univ Belfast | Composition |
EP2138527A1 (fr) * | 2008-06-24 | 2009-12-30 | Freie Universität Berlin | Nanoparticules, procédé pour la production de nanoparticules, système de nanoparticules et utilization du système de nanoparticules |
CN101628970B (zh) * | 2008-07-15 | 2011-07-27 | 国家纳米科学中心 | 一种超支化聚合物及其制备方法和应用 |
JP5694964B2 (ja) | 2009-02-23 | 2015-04-01 | ノクシライザー, インコーポレイテッドNoxilizer, Incorporated | ガス滅菌装置及びガス滅菌方法 |
KR100911249B1 (ko) | 2009-04-29 | 2009-08-07 | 다이아텍코리아 주식회사 | 신규한 클로린 e6-엽산 결합 화합물 |
EP2488591A1 (fr) * | 2009-10-13 | 2012-08-22 | Novan, Inc. | Revêtements libérant de l'oxyde nitrique |
CA2787156C (fr) | 2010-01-19 | 2020-12-29 | Northwestern University | Nanostructures synthetiques servant a la distribution des oligonucleotides |
DE102010008982A1 (de) * | 2010-02-24 | 2011-08-25 | Bayer Innovation GmbH, 40225 | Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie |
WO2011156895A2 (fr) * | 2010-06-14 | 2011-12-22 | National Research Council Of Canada | Nanoparticules magnétiques et applications associées |
US9212258B2 (en) * | 2011-02-23 | 2015-12-15 | The Board Of Trustees Of The University Of Illinois | Amphiphilic dendron-coils, micelles thereof and uses |
WO2012116177A2 (fr) * | 2011-02-24 | 2012-08-30 | Colorado State University Research Foundation | Matières pour modulation de réponses biologiques et leurs procédés de fabrication |
WO2012125214A1 (fr) * | 2011-03-17 | 2012-09-20 | Transdermal Biotechnology, Inc. | Systèmes topiques d'oxyde nitrique et leurs procédés d'utilisation |
US20150111973A1 (en) * | 2012-03-13 | 2015-04-23 | Novan, Inc. | Methods of modulating steroid hormone activity |
CN102779241B (zh) * | 2012-07-06 | 2015-04-22 | 陕西师范大学 | 基于人工蜂群繁殖机制的ppi网络聚类方法 |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
ES2821528T3 (es) | 2012-11-14 | 2021-04-26 | Grace W R & Co | Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado |
KR101743124B1 (ko) * | 2013-03-07 | 2017-06-02 | 주식회사 아이센스 | 일산화질소를 저장, 전달 할 수 있는 나노섬유의 제조방법 및 이에 의하여 제조된 일산화질소를 저장, 전달 할 수 있는 나노섬유 |
US10576462B2 (en) * | 2013-05-13 | 2020-03-03 | University Of Connecticut | Mesoporous materials and processes for preparation thereof |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
DE102013111584A1 (de) | 2013-10-21 | 2015-05-07 | Federal-Mogul Bremsbelag Gmbh | Trägerkörper für einen Bremsbelag einer Scheibenbremse mit Tilgermasse zur Veränderung der Schwingung |
DE102013111594B4 (de) * | 2013-10-21 | 2015-04-30 | Federal-Mogul Bremsbelag Gmbh | Verfahren zur Herstellung eines Trägerkörpers mit Tilgermasse zur Veränderung der Schwingung für einen Bremsbelag einer Scheibenbremse |
US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
EP3508198A1 (fr) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Libération polyvalente de modulateurs immunitaires par des acides nucléiques sphériques liposomaux pour des applications prophylactiques ou thérapeutiques |
WO2015200148A1 (fr) * | 2014-06-22 | 2015-12-30 | The University Of North Carolina At Chapel Hill | Amélioration des performances analytiques de dispositifs de surveillance en continu de la glycémie par l'intermédiaire de monoxyde d'azote |
WO2016160089A1 (fr) * | 2015-03-27 | 2016-10-06 | Novan, Inc. | Compositions antivirales topiques, systèmes d'administration, et méthodes d'utilisation associées |
EP3173074A4 (fr) | 2014-07-22 | 2018-03-07 | Lemonex Inc. | Composition pour l'administration de matériau bioactif ou d'une protéine, et son utilisation |
KR102427467B1 (ko) * | 2014-08-14 | 2022-07-29 | 롬 앤드 하아스 컴패니 | 방출가능 가스를 갖는 폴리머 |
JP6741673B2 (ja) | 2014-10-06 | 2020-08-19 | イグジキュア, インコーポレーテッドExicure, Inc. | 抗tnf化合物 |
KR101577951B1 (ko) * | 2015-09-23 | 2015-12-16 | 기초과학연구원 | 다공성 코어-쉘 나노입자와 인산칼슘을 이용한 선택적 일산화질소 방출 방법 |
US20180295836A1 (en) * | 2015-10-13 | 2018-10-18 | University Of Central Florida Research Foundation, Inc. | Nanocomposite compositions comprising multi-valent metal material and immobilized quat material, methods of making the compositions and methods of using the compositions |
JP6899154B2 (ja) * | 2015-12-18 | 2021-07-07 | ノースウェスタン ユニバーシティ | 一酸化窒素放出高密度リポタンパク質様ナノ粒子(no hdl nps) |
EP3426316B1 (fr) * | 2016-03-08 | 2023-10-25 | Northwestern University | Administration de phospholipides, de liposomes et de nanoparticules de type lipoprotéines haute densité (hdl nps) libérant de l'oxyde nitrique faisant appel à des endoprothèses à élution médicamenteuse et à l'injection intra-artérielle |
TWI637013B (zh) * | 2016-07-01 | 2018-10-01 | 國防醫學院 | 遞送一氧化氮之複合粒子、其製備方法及其應用 |
EP3338813B1 (fr) | 2016-12-20 | 2020-01-29 | BSN Medical GmbH | Produit de traitement de plaie multicouche ayant une couche de libération perforée |
SG11201907260PA (en) | 2017-02-06 | 2019-09-27 | Lemonex Inc | Physiologically active substance carrier |
US20200163885A1 (en) * | 2017-07-25 | 2020-05-28 | Lemonex Inc. | Composition for delivering physiologically active ingredients into blood vessel |
US11530132B2 (en) | 2017-09-05 | 2022-12-20 | Lemonex Inc. | Composition comprising porous silica particles carrying a cell fate modulating factor |
CN107812188B (zh) * | 2017-10-25 | 2020-09-04 | 暨南大学 | 具有一氧化氮/光热协同抗菌作用的磁性材料及其制备方法与应用 |
CN110269846A (zh) * | 2018-03-15 | 2019-09-24 | 中国科学院上海硅酸盐研究所 | 一种低频脉冲电场响应的靶向释药体系 |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
CN109276577B (zh) * | 2018-11-01 | 2021-04-02 | 重庆大学 | 一种一氧化氮纳米复合水凝胶及其制备方法和应用 |
CN109395087A (zh) * | 2018-12-17 | 2019-03-01 | 上海交通大学医学院 | 一种共递送no供体和纳米药物的纳米共递送系统 |
CN109674764B (zh) * | 2019-01-10 | 2021-06-01 | 四川大学 | 一种抗肿瘤磁性载药杂化纳米胶囊及其制备方法 |
WO2020198646A1 (fr) * | 2019-03-27 | 2020-10-01 | The Texas A&M University System | Administration intracellulaire et ciblage mitochondrial par fluoration |
WO2020257641A1 (fr) * | 2019-06-19 | 2020-12-24 | Zylo Therapeutics, Inc. | Monolithes fonctionnalisés par du soufre et particules dérivées de ceux-ci en tant que transporteur d'oxyde nitrique pour des applications pharmaceutiques et cosmétiques |
JP2023513106A (ja) * | 2020-02-07 | 2023-03-30 | ノウ・バイオ・エルエルシー | 一酸化窒素放出抗菌化合物、製剤、およびそれらに関連する方法 |
US11191888B1 (en) | 2020-05-18 | 2021-12-07 | Agitated Solutions Inc. | Syringe-based microbubble generator |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507466A (en) * | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
US4558120A (en) * | 1983-01-07 | 1985-12-10 | The Dow Chemical Company | Dense star polymer |
US4568737A (en) * | 1983-01-07 | 1986-02-04 | The Dow Chemical Company | Dense star polymers and dendrimers |
US4587329A (en) * | 1984-08-17 | 1986-05-06 | The Dow Chemical Company | Dense star polymers having two dimensional molecular diameter |
US4631337A (en) * | 1983-01-07 | 1986-12-23 | The Dow Chemical Company | Hydrolytically-stable dense star polyamine |
US4694064A (en) * | 1986-02-28 | 1987-09-15 | The Dow Chemical Company | Rod-shaped dendrimer |
US4713975A (en) * | 1986-05-30 | 1987-12-22 | The Dow Chemical Company | Dense star polymers for calibrating/characterizing sub-micron apertures |
US4737550A (en) * | 1983-01-07 | 1988-04-12 | The Dow Chemical Company | Bridged dense star polymers |
US4857599A (en) * | 1988-02-08 | 1989-08-15 | The Dow Chemical Company | Modified dense star polymers |
US4871779A (en) * | 1985-12-23 | 1989-10-03 | The Dow Chemical Company | Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities |
US5418301A (en) * | 1992-02-26 | 1995-05-23 | Perstorp Ab | Dendritic macromolecule and process for preparation thereof |
US6180082B1 (en) * | 1997-11-24 | 2001-01-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method to enhance tissue accumulation of radiolabeled compounds |
US6471968B1 (en) * | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
US20030032681A1 (en) * | 2001-05-18 | 2003-02-13 | The Regents Of The University Of Clifornia | Super-hydrophobic fluorine containing aerogels |
US20030203915A1 (en) * | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
US20040076582A1 (en) * | 2002-08-30 | 2004-04-22 | Dimatteo Kristian | Agent delivery particle |
US20040254419A1 (en) * | 2003-04-08 | 2004-12-16 | Xingwu Wang | Therapeutic assembly |
US6841166B1 (en) * | 2001-08-21 | 2005-01-11 | The Regents Of The University Of Michigan | Nitric oxide-releasing polymers incorporating diazeniumdiolated silane derivatives |
US20050037050A1 (en) * | 2003-08-11 | 2005-02-17 | Jan Weber | Medical devices comprising drug-loaded capsules for localized drug delivery |
Family Cites Families (405)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3754368A (en) | 1969-11-04 | 1973-08-28 | Moore Perk Corp | Sterile packaging method |
US4182827A (en) | 1978-08-31 | 1980-01-08 | Union Carbide Corporation | Polyurethane hydrogels having enhanced wetting rates |
US4985023A (en) | 1988-05-09 | 1991-01-15 | Dow Corning Corporation | Antimicrobial superabsorbent articles |
US5045322A (en) | 1988-05-09 | 1991-09-03 | Dow Corning Corporation | Antimicrobial superabsorbent sanitary napkin |
US5035892A (en) | 1988-05-09 | 1991-07-30 | Dow Corning Corporation | Antimicrobial superabsorbent compositions and methods |
US5061487A (en) | 1988-05-09 | 1991-10-29 | Dow Corning Corporation | Antimicrobial superabsorbent compositions and methods |
US4990338A (en) | 1988-05-09 | 1991-02-05 | Dow Corning Corporation | Antimicrobial superabsorbent compositions and methods |
US5079004A (en) | 1990-08-06 | 1992-01-07 | Dow Corning Corporation | Antimicrobial superabsorbent compositions and method |
US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
US5234933A (en) | 1991-10-31 | 1993-08-10 | Board Of Governors Of Wayne State University And Vanderbilt University | Cyclic hydroxamic acids |
DE69231666T2 (de) | 1991-11-14 | 2001-05-10 | Brigham & Womens Hospital | Die nitrosylierung von enzym-sh gruppen als eine therapeutische massnahme |
US6291424B1 (en) | 1991-11-14 | 2001-09-18 | Brigham And Women's Hospital | Nitrosated and nitrosylated heme proteins |
DE4210332C1 (fr) | 1992-03-30 | 1993-07-15 | Gruenenthal Gmbh, 5100 Aachen, De | |
US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
US5238832A (en) | 1992-06-08 | 1993-08-24 | Board Of Governors Of Wayne State University | Aryl aliphatic acids |
US6200558B1 (en) | 1993-09-14 | 2001-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
US5525357A (en) | 1992-08-24 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5650447A (en) | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
US5428070A (en) | 1993-06-11 | 1995-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity |
US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
US5861168A (en) | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US5852058A (en) | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
US6255277B1 (en) | 1993-09-17 | 2001-07-03 | Brigham And Women's Hospital | Localized use of nitric oxide-adducts to prevent internal tissue damage |
US6087479A (en) | 1993-09-17 | 2000-07-11 | Nitromed, Inc. | Localized use of nitric oxide-adducts to prevent internal tissue damage |
WO1995007691A1 (fr) | 1993-09-17 | 1995-03-23 | Brigham And Women's Hospital | Produits d'addition de l'oxyde nitrique utilises dans la prevention de la thrombose sur des surfaces artificielles et vasculaires |
US5650442A (en) | 1993-10-08 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers |
US5840759A (en) | 1993-10-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents |
JPH09508097A (ja) | 1993-11-02 | 1997-08-19 | アメリカ合衆国 | 虚血再灌流傷害における保護剤としての酸化窒素放出化合物の使用 |
US5786332A (en) | 1995-03-06 | 1998-07-28 | Trega Biosciences, Inc. | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels |
US5726156A (en) | 1995-03-06 | 1998-03-10 | Trega Biosciences, Inc. | Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels |
US5599984A (en) | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
US6008255A (en) | 1994-01-21 | 1999-12-28 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
JP3875262B2 (ja) | 1994-02-21 | 2007-01-31 | アバディーン ユニヴァーシティ | 殺菌剤としての酸性化したニトリット |
US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
CN1107499C (zh) | 1994-05-27 | 2003-05-07 | 塞勒吉医药公司 | 用于治疗肛门疾患的氧化氮供体组合物及方法 |
US5504117A (en) | 1994-05-27 | 1996-04-02 | Neptune Pharmaceutical Corporation | Pharmacologic preparation for the treatment of anal disorders |
US6190704B1 (en) | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US6747062B2 (en) | 1994-09-26 | 2004-06-08 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US5519020A (en) | 1994-10-28 | 1996-05-21 | The University Of Akron | Polymeric wound healing accelerators |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
US5810010A (en) | 1995-01-03 | 1998-09-22 | Anbar; Michael | Detection of cancerous lesions by their effect on the periodic modulation of perfusion in the surrounding tissues |
US5999843A (en) | 1995-01-03 | 1999-12-07 | Omnicorder Technologies, Inc. | Detection of cancerous lesions by their effect on the spatial homogeneity of skin temperature |
US6035225A (en) | 1995-01-03 | 2000-03-07 | Omnicorder Technologies | Detection of cancerous lesions by measuring nitric oxide concentrations in tissue |
US5961466A (en) | 1995-01-03 | 1999-10-05 | Omnicorder Technologies, Inc. | Method of detection of cancerous lesions by their effect on the spatial distribution of modulation of temperature and homogeneity of tissue |
EP0805678B1 (fr) * | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation |
US5665077A (en) | 1995-04-24 | 1997-09-09 | Nitrosci Pharmaceuticals Llc | Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis |
US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
DE69637676D1 (de) | 1995-11-09 | 2008-10-23 | Univ R | Verwendung von lokal verabreichten Lysine zur VERBESSERUNG DER VASKULAREN FUNKTION |
US5821261A (en) | 1995-12-08 | 1998-10-13 | Merck & Co., Inc. | Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase |
US6323211B1 (en) | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
US20020061879A1 (en) | 1996-02-02 | 2002-05-23 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US20020143007A1 (en) | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
US5994294A (en) | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
US20050065161A1 (en) | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
US5932538A (en) | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
IT1282686B1 (it) | 1996-02-26 | 1998-03-31 | Nicox Sa | Composti in grado di ridurre la tossicita' da farmaci |
WO1997034014A1 (fr) | 1996-03-15 | 1997-09-18 | Yale University | Procedes et moyen de detection d'une synthase d'oxyde nitrique |
US6143037A (en) | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US5797887A (en) | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
US20030093143A1 (en) | 1999-03-01 | 2003-05-15 | Yiju Zhao | Medical device having surface depressions containing nitric oxide releasing compound |
WO1998008496A1 (fr) | 1996-08-27 | 1998-03-05 | The University Of Akron | Polyamine esters lipophiles permettant l'apport de monoxyde d'azote cible sur un site a des fins pharmaceutiques |
CA2266908C (fr) | 1996-09-27 | 2010-07-20 | Joseph E. Saavedra | Diazen-1-ium-1,2-diolates 1-substitutes o2-aryles ou o2-glycosyles et 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolates o2-subtitutes |
GB9622997D0 (en) | 1996-11-05 | 1997-01-08 | Univ St Andrews | Nitric oxide donor drugs |
US5958427A (en) | 1996-11-08 | 1999-09-28 | Salzman; Andrew L. | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications |
US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
US5891472A (en) | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
DE69739663D1 (de) | 1996-12-31 | 2009-12-31 | Antioxidant Pharmaceuticals Co | Pharmazeutische glutathionpräparate und methoden zu dern verabreichung |
US6896899B2 (en) | 1996-12-31 | 2005-05-24 | Antioxidant Pharmaceuticals Corp. | Pharmaceutical preparations of glutathione and methods of administration thereof |
US6070928A (en) | 1997-01-17 | 2000-06-06 | Cascade Engineering, Inc. | Mat with integrally molded door |
US6160021A (en) | 1997-02-04 | 2000-12-12 | The General Hospital Corporation | Method for treating epidermal or dermal conditions |
US6034752A (en) | 1997-03-22 | 2000-03-07 | Kent Displays Incorporated | Display device reflecting visible and infrared radiation |
IL120531A (en) | 1997-03-26 | 2006-12-31 | Yissum Res Dev Co | Nitric oxide donors and pharmaceutical compositions containing them |
US6171232B1 (en) | 1997-06-26 | 2001-01-09 | Cordis Corporation | Method for targeting in vivo nitric oxide release |
JP4856295B2 (ja) | 1997-07-03 | 2012-01-18 | アメリカ合衆国政府 | 新規な一酸化窒素放出アミジン誘導ジアゼニウムジオレート及びその組成物 |
US6796966B2 (en) | 1997-10-15 | 2004-09-28 | Jeffrey E. Thomas | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal |
WO1999018949A1 (fr) | 1997-10-15 | 1999-04-22 | Thomas Jefferson University | Compositions donneur a base d'oxyde nitrique, methodes, appareil et kits de prevention et d'attenuation de la vasoconstriction et de spasmes vasculaires chez un mammifere |
US5994444A (en) | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
CA2219867A1 (fr) | 1997-10-31 | 1999-04-30 | Jiangping Wu | Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique |
DE69826528T2 (de) | 1997-12-23 | 2006-02-23 | Amersham Health As | Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung |
GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
IT1298338B1 (it) | 1998-03-05 | 1999-12-20 | Nicox Sa | Composizioni farmaceutiche per l'ulcera |
US6560478B1 (en) | 1998-03-16 | 2003-05-06 | The Research Foundation Of City University Of New York | Method and system for examining biological materials using low power CW excitation Raman spectroscopy |
US6151522A (en) | 1998-03-16 | 2000-11-21 | The Research Foundation Of Cuny | Method and system for examining biological materials using low power CW excitation raman spectroscopy |
US5962520A (en) | 1998-04-02 | 1999-10-05 | The University Of Akron | Hydrolytically unstable, biocompatible polymer |
US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
US6207855B1 (en) | 1998-06-23 | 2001-03-27 | Duke University Medical Center | Stable no-delivering compounds |
US20020068365A1 (en) | 1998-07-28 | 2002-06-06 | Eric H. Kuhrts | Controlled release nitric oxide producing agents |
US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
US6299980B1 (en) | 1998-09-29 | 2001-10-09 | Medtronic Ave, Inc. | One step lubricious coating |
US20040043068A1 (en) | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
US6379691B1 (en) | 1998-09-29 | 2002-04-30 | Medtronic/Ave, Inc. | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
US20070086954A1 (en) | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
CA2254645A1 (fr) | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Methode et appareil pour traiter les infections respiratoires par l'inhalation d'oxyde nitrique |
US20070275100A1 (en) | 1998-11-23 | 2007-11-29 | Miller Christopher C | Use of gaseous nitric oxide as an anti-cancer agent |
US6261594B1 (en) | 1998-11-25 | 2001-07-17 | The University Of Akron | Chitosan-based nitric oxide donor compositions |
US6238683B1 (en) | 1998-12-04 | 2001-05-29 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
US7179475B1 (en) | 1998-12-04 | 2007-02-20 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
GB9905425D0 (en) | 1999-03-09 | 1999-05-05 | Queen Mary & Westfield College | Pharmaceutical composition |
US20050142218A1 (en) | 2000-03-09 | 2005-06-30 | Queen Mary & Westfield College | Pharmaceutical composition containing nitrate source and an acidifying agent for treating skin ischaemia |
US6312663B1 (en) | 1999-03-19 | 2001-11-06 | Joseph V. Boykin, Jr. | Prediction of diabetes impaired wound healing by urinary nitrate assay |
US6562785B1 (en) | 1999-03-23 | 2003-05-13 | Howard M. Shapiro | Method for overcoming bacterial antibiotic resistance |
CA2377373C (fr) | 1999-06-14 | 2011-05-10 | Henry Ford Health System | Donneurs d'oxyde nitrique induisant la neurogenese |
US7135498B1 (en) | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
US7655423B2 (en) | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
US20010012851A1 (en) | 1999-07-29 | 2001-08-09 | Kristin M. Lundy | Nitric oxide releasing oxindole prodrugs for anagesic, anti-inflammatory and disease-modifying use |
US20020049157A1 (en) | 1999-08-25 | 2002-04-25 | Jiangping Wu | Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
US7052711B2 (en) | 1999-09-02 | 2006-05-30 | Rice University | Nitric oxide-producing hydrogel materials |
WO2001015738A2 (fr) | 1999-09-02 | 2001-03-08 | Rice University | Materiaux hydrogels produisant du monoxyde d'azote |
US7279176B1 (en) | 1999-09-02 | 2007-10-09 | Rice University | Nitric oxide-producing hydrogel materials |
US6737447B1 (en) | 1999-10-08 | 2004-05-18 | The University Of Akron | Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof |
IL150361A0 (en) | 1999-12-20 | 2002-12-01 | Majeste La Reine Du Cheff Du C | Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
US6492405B2 (en) | 1999-12-30 | 2002-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nitric oxide donors and pharmaceutical compositions containing them |
AU2001234538A1 (en) | 2000-01-24 | 2001-07-31 | Dzgenes, L.L.C. | Nitric oxide synthase gene diagnostic polymorphisms |
US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
US6699846B2 (en) | 2000-03-17 | 2004-03-02 | Corixa Corporation | Mono- and disaccharides for the treatment of nitric oxide related disorders |
MXPA02009236A (es) | 2000-03-20 | 2004-04-05 | Novovascular Inc | Matrices que contienen donadores de oxido nitrico y agentes reductores, y su uso. |
US20010038832A1 (en) | 2000-04-11 | 2001-11-08 | Benjamin Bonavida | Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity |
EP1278547B1 (fr) | 2000-04-26 | 2004-11-03 | Cellegy Pharmaceuticals, Inc | Formulations et methodes d'utilisation d'agents mimetiques de l'oxyde nitrique contre un phenotype cellulaire malin |
US7678391B2 (en) | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US20050142217A1 (en) | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US20010053772A1 (en) | 2000-04-28 | 2001-12-20 | Benjamin Bonavida | Aza analogues of alkyl lysophospholipids exert immunomodulatory effects |
US6270779B1 (en) * | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
WO2001089519A1 (fr) | 2000-05-22 | 2001-11-29 | Nitromed, Inc. | Inhibiteurs de thromboxane, compositions, procedes d'utilisation et applications correspondantes |
US6538033B2 (en) | 2000-08-29 | 2003-03-25 | Huntington Medical Research Institutes | Nitric oxide donor compounds |
GB0021317D0 (en) | 2000-08-30 | 2000-10-18 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
JP4841066B2 (ja) | 2000-09-01 | 2011-12-21 | ライスユニバーシティ | 酸化窒素生成ヒドロゲル物質 |
GB0022084D0 (en) | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
US6410622B1 (en) | 2000-09-11 | 2002-06-25 | Gregory W. Endres | Method of preventing fouling organisms in marine environments and polymer-bound nitric oxide/nitric oxide-releasing compositions usable therefor |
JP4194364B2 (ja) | 2000-10-16 | 2008-12-10 | デューク・ユニバーシティ | 嚢胞性繊維症におけるエアロゾル化されたs−ニトロソグルタチオンの治療的使用 |
WO2002032413A2 (fr) | 2000-10-17 | 2002-04-25 | Board Of Regents, The University Of Texas System | Procede servant a incorporer du n-(4-hydroxyphenyl) retinamide dans des liposomes |
US7049308B2 (en) | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
KR100383149B1 (ko) | 2000-12-12 | 2003-05-12 | 한국생명공학연구원 | 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도 |
DE10063937A1 (de) | 2000-12-20 | 2002-07-18 | Bayer Ag | Verfahren zur Herstellung von Trimethylolverbindungen und Ameisensäure |
US6780849B2 (en) | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
US7329412B2 (en) | 2000-12-22 | 2008-02-12 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical devices containing chlorhexidine free base and salt |
US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US20040009238A1 (en) | 2002-07-09 | 2004-01-15 | Chris Miller | Exogenenous nitric oxide gas (gNO) therapy in wound healing |
US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
CA2433803A1 (fr) | 2001-01-16 | 2002-07-25 | Mark E. Meyerhoff | Generation biocatalytique et biomimetique in situ d'oxyde nitrique sur des interfaces substrat/sang |
US7128904B2 (en) | 2001-01-16 | 2006-10-31 | The Regents Of The University Of Michigan | Material containing metal ion ligand complex producing nitric oxide in contact with blood |
US7335383B2 (en) | 2001-01-16 | 2008-02-26 | The Regents Of The University Of Michigan | Generation of nitric oxide in vivo from nitrite, nitrate or nitrosothiols endogenous in blood |
US6706274B2 (en) | 2001-01-18 | 2004-03-16 | Scimed Life Systems, Inc. | Differential delivery of nitric oxide |
ITMI20010426A1 (it) | 2001-03-01 | 2002-09-01 | Consiglio Nazionale Ricerche | Donatori di ossido di azoto basati su centri metallici |
US7012098B2 (en) | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
US20020138051A1 (en) | 2001-03-26 | 2002-09-26 | Hole Douglas R. | System and method for the prevention and treatment of animal wound infections using nitric oxide |
WO2002096387A1 (fr) | 2001-05-25 | 2002-12-05 | Medtronic, Inc. | Dispositif medical implantable equipe d'un systeme de liberation controlee d'agents gazeux |
ES2180446B1 (es) | 2001-07-02 | 2004-01-16 | Esteve Labor Dr | Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. |
WO2003006427A1 (fr) | 2001-07-12 | 2003-01-23 | Johns Hopkins University | Composes liberant du monoxyde d'azote a debit regule par photolyse |
GB0119011D0 (en) | 2001-08-03 | 2001-09-26 | Univ Aberdeen | Treatment of nail infections |
CA2459647A1 (fr) | 2001-08-20 | 2003-02-27 | University Of Virginia Patent Foundation | Utilisation de signalisation s-nitrosothiol pour le traitement de troubles du controle respiratoire |
US7135189B2 (en) | 2001-08-23 | 2006-11-14 | Boston Scientific Scimed, Inc. | Compositions and techniques for localized therapy |
CA2459891C (fr) | 2001-09-05 | 2014-02-04 | Cyterra Corporation | Methode et appareil de production d'oxyde nitrique |
US6673338B1 (en) * | 2001-09-10 | 2004-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same |
AU2002336761A1 (en) | 2001-09-26 | 2003-04-07 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | Nitric oxide-releasing coated medical devices and method of preparing same |
US6703046B2 (en) | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
EP1300083A1 (fr) | 2001-10-04 | 2003-04-09 | Societe Des Produits Nestle S.A. | Produit snack à base de lait |
GB0125222D0 (en) | 2001-10-19 | 2001-12-12 | Barts & London Nhs Trust | Composition for the treatment of microbial infections |
US20040110691A1 (en) | 2001-11-13 | 2004-06-10 | Stamler Jonathan S. | Thiol reactive agents as a therapeutic modality |
US6627602B2 (en) | 2001-11-13 | 2003-09-30 | Duke University | Preventing desensitization of receptors |
US6472390B1 (en) | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
MXPA04005332A (es) | 2001-12-03 | 2005-05-16 | Bard Inc C R | Dispositivo medico resistente a microbios, revestimiento polimerico resistente a microbios y metodos para producir los mismos. |
AU2003205058A1 (en) | 2002-01-08 | 2003-07-24 | Bernard Techologies, Inc. | Antimicrobial body covering articles |
WO2003059339A1 (fr) | 2002-01-15 | 2003-07-24 | Trustees Of Dartmouth College | Derives de bis- enone tricyclique et methodes d'utilisation |
CA2480033C (fr) | 2002-03-21 | 2011-05-10 | The University Of Utah Research Foundation | Utilisation in vivo de donneurs d'oxyde nitrique actives par la glutathion s-transferase |
WO2003092763A1 (fr) | 2002-05-03 | 2003-11-13 | Duke University | Nanotubes de carbone destines au stockage d'oxyde nitrique |
EP1507526A2 (fr) | 2002-05-07 | 2005-02-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Polyamines cycliques polydiazeniumdiolees liberant de l'acide nitrique polyphasique, composes et compositions les comprenant, et procedes d'utilisation associes |
WO2004064723A2 (fr) | 2002-05-13 | 2004-08-05 | Trustees Of Dartmouth College | Inhibiteurs et procedes d'utilisation de ceux-ci |
CA2490392A1 (fr) | 2002-06-21 | 2003-12-31 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Utilisation pharmaceutique du monoxyde d'azote, de l'heme oxygenase-1 et des produits de la degradation de l'heme |
US7070798B1 (en) | 2002-06-21 | 2006-07-04 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine |
US6949530B2 (en) | 2002-07-18 | 2005-09-27 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same |
WO2004009253A1 (fr) * | 2002-07-19 | 2004-01-29 | University Of North Carolina At Chapel Hill | Liberation localisee en surface d'un agent anti-encrassement biologique par l'intermediaire de micro-compositions |
AU2003252515A1 (en) | 2002-07-26 | 2004-02-16 | Merck Frosst Canada And Co. | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
AU2003281815A1 (en) | 2002-08-02 | 2004-02-23 | The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Hu | Cross-linked nitric oxide-releasing polyamine coated substrates, compositions comprising same and method of making same |
US20040033480A1 (en) | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
US20050080021A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
US20050080024A1 (en) | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
US6951902B2 (en) | 2002-08-16 | 2005-10-04 | Michigan Biotechnology Institute | Two dimensional polymer that generates nitric oxide |
US7674482B2 (en) | 2002-08-27 | 2010-03-09 | Targeted Medical Pharma Inc. | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods |
US20030039697A1 (en) | 2002-09-12 | 2003-02-27 | Yi-Ju Zhao | Matrices containing nitric oxide donors and reducing agents and their use |
CA2503063A1 (fr) | 2002-10-22 | 2004-05-06 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Inhibiteurs selectifs de la cyclo-oxygenase-2 liberant de l'oxyde nitrique |
US20080317679A1 (en) | 2002-10-25 | 2008-12-25 | Foamix Ltd. | Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses |
JP4733393B2 (ja) | 2002-11-18 | 2011-07-27 | ポラリス・グループ | インビボでウイルス複製を阻害する方法 |
AU2003293529A1 (en) | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
WO2004064767A2 (fr) | 2003-01-23 | 2004-08-05 | Kahn Nighat N | Agents inducteurs d'oxyde nitrique |
FR2850578B1 (fr) | 2003-02-03 | 2006-07-28 | Oreal | Utilisation de n-arylmethylene ethylenediaminetriacetates, n-arylmethyleneiminodiacetates ou n,n'-diarylmethylene ethylenediamineacetates comme donneurs de no |
US7169809B2 (en) | 2003-03-05 | 2007-01-30 | Merck Frosst Company | Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors |
AU2004237574A1 (en) | 2003-03-13 | 2004-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
SE0300971D0 (sv) | 2003-04-03 | 2003-04-03 | Aga Ab | Nitric oxide in treatment of inflammation |
US20050079132A1 (en) * | 2003-04-08 | 2005-04-14 | Xingwu Wang | Medical device with low magnetic susceptibility |
US7972137B2 (en) | 2003-06-30 | 2011-07-05 | Rosen Gerald M | Anti-microbial dental formulations for the prevention and treatment of oral mucosal disease |
BRPI0412273B1 (pt) | 2003-07-03 | 2019-09-24 | The University Court Of The University Of St. Andrews | Preparação farmacêutica, uso de um material de zeólito, artigo médico, produto cosmético e/ou de higiene pessoal, e, método de liberação de óxido nítrico |
US7234079B2 (en) | 2003-07-11 | 2007-06-19 | Agency For Science, Technology & Research | Method and system for enabling recovery of data stored in a computer network; a method and a system for recovering data stored in a computer network |
US20050054714A1 (en) | 2003-07-17 | 2005-03-10 | Benito Munoz | Nitric oxide releasing drugs for Alzheimer's disease |
EP1648527A4 (fr) | 2003-07-25 | 2008-04-23 | Univ Akron | Stabilisation et declenchement ionique de la liberation d'oxyde nitrique |
US7314857B2 (en) | 2003-08-25 | 2008-01-01 | Kane Biotech Inc. | Synergistic antimicrobial compositions and methods of inhibiting biofilm formation |
US7282519B2 (en) | 2003-08-28 | 2007-10-16 | Nitromed, Inc. | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use |
AU2004275868A1 (en) | 2003-09-26 | 2005-04-07 | David R. Whitlock | Methods of using ammonia oxidizing bacteria |
EP1673384A4 (fr) | 2003-09-26 | 2007-02-07 | Nitromed Inc | Composes d'acide glutamique nitroses, leurs compositions et procedes d'utilisation |
US7485324B2 (en) | 2003-09-29 | 2009-02-03 | Pulmonox Technologies Corporation | Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms |
US20050074506A1 (en) | 2003-10-02 | 2005-04-07 | Brainsgate Ltd. | Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders |
EP1677849A1 (fr) | 2003-10-14 | 2006-07-12 | Cube Medical A/S | Ballonnet utilisable en angioplastie |
US20070059351A1 (en) | 2003-10-17 | 2007-03-15 | Murrell George A C | Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods |
US20060286158A1 (en) | 2003-10-17 | 2006-12-21 | Calvert Murrell George A | Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents |
US20050171199A1 (en) | 2003-10-17 | 2005-08-04 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents |
US20060286159A1 (en) | 2003-10-17 | 2006-12-21 | Calvert Murrell George A | Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect |
US20070053966A1 (en) | 2003-10-17 | 2007-03-08 | Robert Ang | Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue |
EP1694399B1 (fr) | 2003-12-15 | 2011-11-02 | Nitricare HB | Dispositif d'administration d'agents thérapeutiques |
US8017074B2 (en) | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
JP2007521118A (ja) | 2004-01-07 | 2007-08-02 | ノクシライザー,インコーポレイテッド | 殺菌システムおよび装置 |
CA2554716A1 (fr) | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Composes nitroses et/ou nitrosyles, compositions et procede pour les utiliser |
AU2005207039A1 (en) | 2004-01-22 | 2005-08-04 | Reneker, Darrell | Polymer NO donor predrug nanofiber coating for medical devices and therapy |
CN1914169A (zh) | 2004-01-27 | 2007-02-14 | 默克弗罗斯特公司 | 作为环氧合酶-2抑制剂的二芳基-2-(5h)-呋喃酮的氧化氮释放前药 |
CA2554333A1 (fr) | 2004-01-27 | 2005-08-04 | Merck Frosst Company | Promedicaments liberant de l'oxyde nitrique de diaryl-2-(5h)-furanones utilises en tant qu'inhibiteurs de cyclooxygenase-2 |
US20050165452A1 (en) | 2004-01-28 | 2005-07-28 | Medtronic, Inc. | Antithrombogenic medical device |
US7569559B2 (en) | 2004-02-09 | 2009-08-04 | Noxilizer, Inc. | Nitric oxide-releasing molecules |
EP1718603A4 (fr) | 2004-02-09 | 2009-09-23 | Noxilizer Inc | Molecules liberant du monoxyde d'azote |
WO2005077962A2 (fr) | 2004-02-10 | 2005-08-25 | Purdue Research Foundation | Complexes metal-dithiocarbamate a structure en couronne et leurs procedes d'utilisation |
JP5376761B2 (ja) | 2004-02-23 | 2013-12-25 | ストラテジック サイエンス アンド テクノロジーズ, エルエルシー | 身体の外観および皮膚の外観を改善するための、一酸化窒素の局所送達 |
AU2005239995A1 (en) | 2004-03-31 | 2005-11-17 | Nitromed, Inc. | Methods for treating blood disorders with nitric oxide donor compounds |
CA2563678A1 (fr) | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Effets benefiques de l'augmentation du debit sanguin local |
WO2005115440A2 (fr) | 2004-04-29 | 2005-12-08 | Kahn Nighat N | Compositions et procede destines a la modulation de l'oxyde nitrique synthase activee par l'insuline |
CA2565556A1 (fr) | 2004-05-03 | 2005-12-08 | Neosil, Inc. | Medicament antimicrobien polycationique |
US20050265958A1 (en) | 2004-05-14 | 2005-12-01 | West Jennifer L | Nitric oxide releasing compositions and associated methods |
US8791073B2 (en) | 2004-05-14 | 2014-07-29 | William Marsh Rice University | Peptide-modified polyurethane compositions and associated methods |
US7582623B2 (en) | 2004-05-20 | 2009-09-01 | The Regents Of The University Of California | Photoactive metal nitrosyls for blood pressure regulation and cancer therapy |
DE602005018222D1 (fr) | 2004-06-10 | 2010-01-21 | Nippon Kayaku Kk | |
US20060008529A1 (en) | 2004-07-12 | 2006-01-12 | Meyerhoff Mark E | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers |
KR100625931B1 (ko) | 2004-07-29 | 2006-09-20 | 매그나칩 반도체 유한회사 | 비동기적 입력신호의 선입선처리장치 |
US20060039950A1 (en) | 2004-08-23 | 2006-02-23 | Zhengrong Zhou | Multi-functional biocompatible coatings for intravascular devices |
EP1794195B1 (fr) | 2004-09-27 | 2014-12-17 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Polymeres diazeniumdiolates a base d'acrylonitrile liberant du monoxyde d'azote et compositions, dispositifs medicaux et utilisations correspondantes |
US20070154570A1 (en) | 2004-09-29 | 2007-07-05 | Miller Christopher C | Use of nitric oxide in the treatment and disinfection of biofilms |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
FR2877004B1 (fr) | 2004-10-21 | 2007-03-09 | Oreal | Esters et amides silaniques d'acide 2-oxothiazolidine-4- carboxylique et leurs utilisations cosmetiques. |
US8388677B2 (en) * | 2004-10-29 | 2013-03-05 | Boston Scientific Scimed, Inc. | Anti-thrombogenic and anti-restenotic vascular medical devices |
US20080275093A1 (en) | 2004-11-15 | 2008-11-06 | Nitromed, Inc. | Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use |
CA2588744A1 (fr) | 2004-11-29 | 2006-06-01 | The University Of Akron | Dispositifs donneurs de monoxyde d'azote topiques et leurs methodes d'utilisation a des fins therapeutiques |
EP1681068A1 (fr) | 2004-12-16 | 2006-07-19 | NOLabs AB | Dispositif de filtration à élution de monoxyde d'azote |
WO2006064056A2 (fr) | 2004-12-16 | 2006-06-22 | Nolabs Ab | Dispositif et procedes de filtrage anti-elements pathogenes ou cancereux faisant appel a de l'oxyde nitrique |
US20090143417A1 (en) | 2004-12-24 | 2009-06-04 | The University Of Queensland | Methods of treating pain |
EP1848424B1 (fr) | 2005-01-31 | 2017-04-05 | Mylan Laboratories, Inc | Preparation pharmaceutique comprenant du nebivolol hydroxyle |
WO2006084914A2 (fr) | 2005-02-11 | 2006-08-17 | Nolabs Ab | Dispositif de traitement gastrique, procede de fabrication associe et utilisation d'oxyde nitrique |
WO2006084911A2 (fr) | 2005-02-11 | 2006-08-17 | Nolabs Ab | Dispositif d'application de medicaments ameliore, procede de fabrication de celui-ci et procede de traitement |
EP1690554A1 (fr) | 2005-02-11 | 2006-08-16 | NOLabs AB | Dispositif utilisé pour le traitement des infections comprenant l'onychomycose et la dermatophytose |
EP1690532A1 (fr) | 2005-02-11 | 2006-08-16 | NOLabs AB | Dispositif pour traitement gastrique et son procédé de fabrication |
EP1700611A1 (fr) | 2005-02-11 | 2006-09-13 | NOLabs AB | Dispositif de traitement de troubles dans la cavité buccale et son procédé de fabrication |
MX2007009690A (es) | 2005-02-11 | 2007-10-15 | Nolabs Ab | Dispositivo, metodo y uso para tratamiento de neuropatias que implican oxido nitrico. |
EP1690557A1 (fr) | 2005-02-11 | 2006-08-16 | NOLabs AB | Dispositif de traitement de troubles rectals et son procédé de fabrication |
PT1861130E (pt) | 2005-02-11 | 2008-12-02 | Nolabs Ab | Dispositivo e método para o tratamento de dermatomicose, e em particular de onicomicose |
WO2006084913A2 (fr) | 2005-02-11 | 2006-08-17 | Nolabs Ab | Dispositif pour traiter des troubles rectaux, et procede de fabrication associe comportant de l'oxyde nitrique |
EP1690558A1 (fr) | 2005-02-11 | 2006-08-16 | NOLabs AB | Dispositif de traitment de troubles d'origine diabetique |
EP1757278A1 (fr) | 2005-08-23 | 2007-02-28 | NOLabs AB | Dispositif, système ou méthode contenant un liquide microencapsulé pour la libération d'oxyde nitrique à partir d'un polymère |
JP2008530226A (ja) | 2005-02-16 | 2008-08-07 | ニトロメッド インコーポレーティッド | 抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法 |
CA2597460A1 (fr) | 2005-02-24 | 2006-08-31 | Nitromed, Inc. | Compositions et composes diuretiques renforcateurs d'oxyde nitrique, et leurs procedes d'utilisation |
US8119840B2 (en) | 2005-03-04 | 2012-02-21 | The University Of Akron | Ethambutol based nitric oxide donors |
CA2597444A1 (fr) | 2005-03-09 | 2006-09-21 | Nitromed, Inc. | Sels organiques d'antagonistes de l'angiotensine ii augmentant le taux de monoxyde d'azote endogene, compositions et procedes d'utilisation correspondants |
GB0505035D0 (en) | 2005-03-11 | 2005-04-20 | Insense Ltd | Improvements relating to skin dressings |
WO2006097348A1 (fr) | 2005-03-15 | 2006-09-21 | L'oreal | Utilisation d’agents comme les donneurs d’oxyde nitrique non polymeriques pour rendre les levres a nouveau charnues et/ou colorer les levres |
EP1704877A1 (fr) | 2005-03-24 | 2006-09-27 | NOLabs AB | Dispositif de traitement des plaies comprenant un polymère à élution de monoxyde d'azote |
DE602006006432D1 (de) | 2005-03-24 | 2009-06-04 | Nolabs Ab | Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür |
EP1704876A1 (fr) * | 2005-03-24 | 2006-09-27 | NOLabs AB | Traitement cosmétique, dispositif pour application du traitment et méthode de production |
WO2006100156A2 (fr) | 2005-03-24 | 2006-09-28 | Nolabs Ab | Dispositif d'acces medical intravasculaire, interstitiel ou intra-organes et procede de fabrication faisant appel a du monoxyde d'azote |
WO2006100155A1 (fr) | 2005-03-24 | 2006-09-28 | Nolabs Ab | Dispositif pour le soin des plaies, et procede de fabrication associe, impliquant l'utilisation de monoxyde d'azote |
EP1704879A1 (fr) | 2005-03-24 | 2006-09-27 | NOLabs AB | Appareil médical intravasculaire, interstitiel ou d'accès à l'intérieur d'un organe comprenant un polymère à élution de monoxide d'azote |
EP1885375A4 (fr) | 2005-05-16 | 2010-12-01 | Univ Alberta | Nouveaux ains presentant une fraction diazene-1-ium-1,2-diolate donneuse d'oxyde nitrique |
EP1881804B1 (fr) | 2005-05-17 | 2009-09-09 | Syntach AG | Dispositif et necessaire pour le traitement des troubles du systeme de regularisation du rythme cardiaque |
US20090048219A1 (en) | 2005-05-23 | 2009-02-19 | Nitromed Inc. | Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use |
EP2351828B1 (fr) | 2005-05-24 | 2017-10-18 | NewSouth Innovations Pty Limited | Procédés et compositions permettant de réguler le développement de biofilm |
AU2006249323B2 (en) | 2005-05-27 | 2012-08-30 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
WO2006128743A1 (fr) | 2005-06-01 | 2006-12-07 | Nolabs Ab | Aliment pour animaux |
EP1731176A1 (fr) | 2005-06-01 | 2006-12-13 | NOLabs AB | Dispositif de prétraitement comprenant de l'oxyde nitrique |
EP1728438A1 (fr) | 2005-06-01 | 2006-12-06 | NOLabs AB | Aliment pour animeaux |
US20100016790A1 (en) | 2005-06-01 | 2010-01-21 | Tor Peters | Treatment And Pre-Treatment Device, And Manufacturing Method Therefor, Involving Nitric Oxide |
CA2820200C (fr) | 2005-06-09 | 2015-08-18 | Judith Esther Anderson | Preparations et methodes pour l'amelioration de la liberation d'oxyde nitrique |
EP1896091B1 (fr) | 2005-06-30 | 2011-06-22 | Accord Biomaterials, Inc. | Revetements d'oxyde nitrique pour dispositifs medicaux |
US20080241208A1 (en) | 2005-06-30 | 2008-10-02 | Charles Shanley | Methods, Compositions and Devices For Promoting Anglogenesis |
US20080139450A1 (en) | 2005-07-01 | 2008-06-12 | Srinivasa Madhyastha | Antimicrobial Compositions and Uses Thereof |
AU2006265707B2 (en) | 2005-07-01 | 2012-06-14 | Kane Biotech Inc. | Antimicrobial compositions for inhibiting growth and proliferation of a microbial biofilm on medical devices |
BRPI0503201B8 (pt) | 2005-07-28 | 2021-05-25 | Sci Tech Produtos Medicos Ltda | stents revestidos com blendas poliméricas hidrofílicas, eluidoras de óxido nítrico e s-nitrosotióis |
EP1915157A4 (fr) | 2005-08-02 | 2010-09-01 | Nicox Sa | Composes antimicrobiens promoteurs d'oxyde nitrique, compositions et procedes d'utilisation |
WO2007024501A2 (fr) | 2005-08-25 | 2007-03-01 | Medtronic Vascular, Inc. | Polymeres biodegradables liberant de l'oxyde nitrique utiles comme dispositifs medicaux et revetements associes |
US20070060651A1 (en) | 2005-08-26 | 2007-03-15 | Nestec S.A. | Compositions and methods for improving functional vascular cellular survival integrity and reducing apoptosis in ischemia |
US20070048344A1 (en) | 2005-08-31 | 2007-03-01 | Ali Yahiaoui | Antimicrobial composition |
US20070053952A1 (en) | 2005-09-07 | 2007-03-08 | Medtronic Vascular, Inc. | Nitric oxide-releasing polymers derived from modified polymers |
EP1764119A1 (fr) | 2005-09-09 | 2007-03-21 | NOLabs AB | Implants ayant une ostéointégration ameliorée |
US20090010989A1 (en) | 2005-09-12 | 2009-01-08 | N0Labs Ab | Coating For Implants and Implants With Improved Osteointegration, and Manufacturing Method |
US20070088345A1 (en) | 2005-10-13 | 2007-04-19 | Ust Inc. | Applications of HIFU and chemotherapy |
US7531164B2 (en) | 2005-10-21 | 2009-05-12 | Duke University | Preventing bacterial or viral infectivity and composition containing infection preventing additive |
CA2628055C (fr) | 2005-10-31 | 2013-10-01 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Diazeniumdiolates lies par un carbone, liberant de l'oxyde nitrique et derives de polysaccharides |
WO2007053578A2 (fr) | 2005-10-31 | 2007-05-10 | Amulet Pharmaceuticals, Inc. | Revêtements multiphasiques pour stent comprenant en co-élution de l'oxyde nitrique et un médicament |
EP1790335A1 (fr) | 2005-11-14 | 2007-05-30 | NOLabs AB | Une composition et son usage pour la production d'un médicament pour traiter, traiter prophylactiquement et pour prévenir le cancer et/ou les infections des voies urinaires |
EP1954685A4 (fr) | 2005-11-16 | 2009-11-11 | Nitromed Inc | Composes furoxane, compositions et procedes d'utilisation |
US20070116785A1 (en) | 2005-11-18 | 2007-05-24 | Miller Christopher C | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant |
US20070129690A1 (en) | 2005-12-02 | 2007-06-07 | Joel Rosenblatt | Catheter with polymeric coating |
DE602006017886D1 (de) | 2005-12-02 | 2010-12-09 | Michigan Critical Care Consult | Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit |
US20070196327A1 (en) | 2005-12-06 | 2007-08-23 | Amulet Pharmaceuticals, Inc. | Nitric oxide releasing polymers |
JP2009521481A (ja) | 2005-12-21 | 2009-06-04 | ナイトロックス, エルエルシー | 安定なs−ニトロソチオール製剤 |
WO2007084533A2 (fr) | 2006-01-17 | 2007-07-26 | The University Of Akron | Procede de debridement utilisant des dispositifs et des compositions topiques donneurs d'oxyde nitrique |
WO2007087631A2 (fr) | 2006-01-26 | 2007-08-02 | Bebaas, Inc. | Compositions de cobalamine pour le traitement du cancer |
RU2560144C2 (ru) | 2006-02-03 | 2015-08-20 | Никокс Сайенс Ирландия | Выделяющие оксид азота соединения |
US20070202155A1 (en) | 2006-02-03 | 2007-08-30 | Cure Therapeutics, Inc. | Low dose no donor-containing transdermal patch |
EP1983975B1 (fr) | 2006-02-03 | 2015-07-29 | Giulio Cossu | Procédé de traitement de la dystrophie musculaire |
US20070219208A1 (en) | 2006-02-27 | 2007-09-20 | Balaraman Kalyanaraman | Methods for Treating Cancer |
US20070203242A1 (en) | 2006-02-27 | 2007-08-30 | Calwood Nutritionals, Inc. | Method for treating gastric reflux |
US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
US7645749B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol nitroderivatives and use thereof |
US20090186859A1 (en) | 2006-04-24 | 2009-07-23 | The United States Of America, As Represented By The Sec., Dept. Of Health And Human Services | Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods |
US8241619B2 (en) | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
US20080171351A1 (en) | 2006-05-22 | 2008-07-17 | University Of Notre Dame Du Lac | Probes for anionic cell surface detection |
US20090263416A1 (en) | 2006-06-16 | 2009-10-22 | Dawson Karl A | Reduction of antibiotic resistance in bacteria |
US8333997B2 (en) | 2006-06-21 | 2012-12-18 | Albert Einstein College Of Medicine Of Yeshiva University | Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof |
US20080025972A1 (en) | 2006-07-26 | 2008-01-31 | Duke University | Treating sex steriod responsive disorders |
EP2051935B1 (fr) | 2006-07-26 | 2016-09-07 | STMicroelectronics Srl | Utilisation de dérivés de nitroaniline pour la production d'oxyde nitrique |
GB0616350D0 (en) | 2006-08-17 | 2006-09-27 | Univ St Andrews | Adsorption and release of nitric oxide in metal organic frameworks |
EP1895012A1 (fr) | 2006-08-30 | 2008-03-05 | Universitätsklinikum Freiburg | Méthode de l'induction de l'apoptose de cellules tumorales par l'augmentation du niveau d'oxyde d'azote |
GB0618711D0 (en) | 2006-09-22 | 2006-11-01 | Univ Exeter | Agricultural treatment |
GB0623531D0 (en) | 2006-11-25 | 2007-01-03 | Univ St Andrews | Nitric oxide storage and production |
US7862598B2 (en) | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US7975699B2 (en) | 2007-10-30 | 2011-07-12 | The Invention Science Fund I, Llc | Condoms configured to facilitate release of nitric oxide |
US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
US20090110933A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices related to nitric oxide releasing materials |
US20080175881A1 (en) | 2007-01-18 | 2008-07-24 | Boston Scientific Scimed, Inc. | Blood-contacting medical devices for the release of nitric oxide and anti-restenotic agents |
WO2008094275A1 (fr) | 2007-01-30 | 2008-08-07 | New York University | Peptides destinés à être utilisés dans un traitement d'états associés à de l'oxyde nitrique |
CA2677387C (fr) | 2007-02-05 | 2016-06-21 | Nicox S.A. | Composes donneurs d'oxyde nitrique |
US20080193385A1 (en) | 2007-02-08 | 2008-08-14 | Todd Maibach | Compositions and methods for treating neuropathy |
US20080193566A1 (en) | 2007-02-09 | 2008-08-14 | Miller Christopher C | Use of high dose concentrations of gaseous nitric oxide |
WO2008100591A2 (fr) | 2007-02-14 | 2008-08-21 | The General Hospital Corporation | Modulation de la signalisation de l'oxyde nitrique pour normaliser le système vasculaire tumoral |
US7811600B2 (en) | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
JP5172940B2 (ja) | 2007-03-27 | 2013-03-27 | ノーラブズ エービー | 一酸化窒素送達のための局所皮膚送達装置 |
WO2008130567A1 (fr) | 2007-04-20 | 2008-10-30 | Duke University | Source d'oxyde nitrique neutre stable |
WO2008150505A1 (fr) | 2007-06-01 | 2008-12-11 | Amulet Pharmaceuticals, Inc. | Composés, polymères et procédés de traitement d'un dysfonctionnement gastro-intestinal |
JP2010530001A (ja) | 2007-06-15 | 2010-09-02 | イカリア, インコーポレイテッド | 硫化物単独または一酸化窒素との組み合わせを含む組成物およびその使用 |
US8273828B2 (en) | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
JP2010534832A (ja) | 2007-07-26 | 2010-11-11 | デューク・ユニバーシティ | 血液中において結合し化合している酸化窒素の量の測定 |
GB0715554D0 (en) | 2007-08-09 | 2007-09-19 | Insense Ltd | Improvements relating to skin dressings |
GB0715556D0 (en) | 2007-08-09 | 2007-09-19 | Insense Ltd | Improvements relating to skin dressings |
CA2599082A1 (fr) | 2007-08-27 | 2009-02-27 | Ping I. Lee | Complexes polymeres supra-macromoleculaires permettant de reguler la liberation d'oxyde nitrique dans des dispositifs de cicatrisation de blessures |
WO2009071990A2 (fr) | 2007-08-31 | 2009-06-11 | Topigen Pharmaceuticals Inc. | Corticostéroïde donneur de no doté de propriétés pharmacocinétiques, anti-inflammatoires et vasodilatatrices améliorées |
CA2700172A1 (fr) | 2007-09-21 | 2009-03-26 | Enox Biopharma, Inc. | Tubes antimicrobiens liberant un gaz pour drainer l'oreille |
EP2209472A1 (fr) | 2007-10-12 | 2010-07-28 | The University of North Carolina at Chapel Hill | Utilisation d'oxyde nitrique pour amplifier l'efficacité de l'argent et d'autres agents cicatrisants topiques |
US20090112055A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
US8349262B2 (en) | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
US20090112193A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
WO2009064861A2 (fr) | 2007-11-13 | 2009-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polymères de diazéniumdiolate libérant du monoxyde d'azote, compositions, dispositifs médicaux et utilisations de ceux-ci |
WO2009073643A2 (fr) | 2007-12-03 | 2009-06-11 | Cleveland State University | Revêtements à libération d'oxyde nitrique incorporant une enzyme oxyde nitrique synthase |
EP2224922A4 (fr) | 2007-12-12 | 2010-12-22 | Unicamp | Utilisation de dérivés de phtalamide et/ou de sulfonamide dans le traitement de maladies pour lesquelles une réduction des taux de tnf- et l'utilisation d'une source exogène d'oxyde nitrique sont nécessaires, dérivés de phtalamide, dérivés de sulfonamides, et procédé de production d'un dérivé de sulfonamide |
IE20070934A1 (en) | 2007-12-21 | 2009-06-24 | Trinity College Dublin | Efficient aspirin prodrugs |
WO2009086470A2 (fr) | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Composés permettant d'obtenir du nitrite et de l'oxyde nitrique aérosolisés et leurs utilisations |
EP3058942B2 (fr) | 2008-01-04 | 2023-03-22 | Société des Produits Nestlé S.A. | Compositions comprenant des acides gras insaturés et des composés libérant de l'oxyde nitrique et leur utilisation pour améliorer des fonctions cognitives et apparentées |
US8720436B2 (en) | 2008-01-31 | 2014-05-13 | Genosys, Inc. | Nitric oxide gel apparatus and method |
JP5623916B2 (ja) | 2008-01-31 | 2014-11-12 | バンダービルト・ユニバーシティVanderbilt University | 動脈瘤性くも膜下出血及び血管痙攣に対する医薬組成物 |
US8003811B2 (en) | 2008-02-07 | 2011-08-23 | Nicox S.A. | Nitric oxide donor compounds |
US20090222088A1 (en) | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
US20090232863A1 (en) | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
US20090232868A1 (en) | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
WO2009124379A1 (fr) | 2008-04-09 | 2009-10-15 | Enox Biopharma, Inc. | Cathéters et tubulures inhibant la formation de biofilm |
WO2009131931A1 (fr) | 2008-04-21 | 2009-10-29 | 3M Innovative Properties Company | Compositions libérant de l’oxyde nitrique, dispositifs et procédés |
CA2728789A1 (fr) | 2008-06-24 | 2009-12-30 | Micropharma Limited | Compositions d'oxyde nitrique et dispositifs et procedes pour resultats cosmetiques |
US8852640B2 (en) | 2008-07-03 | 2014-10-07 | Ecole Polytechnique Federale De Lausanne (Epfl) | Micelles for delivery of nitric oxide |
US20100040703A1 (en) | 2008-08-13 | 2010-02-18 | Chris Miller | Use of nitric oxide |
EP2331606B1 (fr) | 2008-09-19 | 2016-11-02 | Northwestern University | Polymères biodégradables générant de l'oxyde nitrique et dispositifs biomédicaux associés |
US7807716B2 (en) | 2008-09-24 | 2010-10-05 | Oral Delivery Technology Ltd. | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use |
US20100086530A1 (en) | 2008-10-06 | 2010-04-08 | Martinov Norman P | Cancer-tumor necrosis by artery nutrient-oxygen blocking |
WO2010045465A1 (fr) | 2008-10-15 | 2010-04-22 | The University Of Tennessee Research Foundation | Procédé et dispositif de détection de la concentration d’un médicament biodisponible dans un fluide |
WO2010048724A1 (fr) | 2008-10-30 | 2010-05-06 | Chris Miller | Pansements libérant de l'oxyde nitrique |
WO2010051378A1 (fr) | 2008-10-31 | 2010-05-06 | Noxilizer, Inc. | Stérilisation de poudre |
US8158187B2 (en) | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
US20100197702A1 (en) | 2009-02-04 | 2010-08-05 | Hellberg Mark R | Ophthalmic composition with nitric oxide donor compound and method of forming and using same |
US8062653B2 (en) | 2009-02-18 | 2011-11-22 | Bezwada Biomedical, Llc | Controlled release of nitric oxide and drugs from functionalized macromers and oligomers |
EP2398761A4 (fr) | 2009-02-18 | 2015-11-04 | Bezwada Biomedical Llc | Libération contrôlée d'oxyde nitrique et de médicaments à parti de macromères et d'oligomères fonctionnalisés |
US9278113B2 (en) | 2009-03-30 | 2016-03-08 | The Board Of Regents, The University Of Texas System | Titanium dioxide nanotubes for production and delivery of nitric oxide and methods for production thereof |
US8236341B2 (en) | 2009-04-02 | 2012-08-07 | Medtronic Vascular, Inc. | Poly(tetrafluoroethylene) polymer with nitric oxide donating surface |
US8709465B2 (en) | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
WO2010151505A1 (fr) | 2009-06-22 | 2010-12-29 | Geno Llc | Thérapies par oxyde nitrique |
CN102711729B (zh) | 2009-08-21 | 2015-04-01 | 诺万公司 | 局部用凝胶 |
US20110059189A1 (en) | 2009-09-08 | 2011-03-10 | Cisne Enterprises Inc. | Method and composition for treating cancer, effecting apoptosis and treating retroviral infections |
EP2665763B1 (fr) | 2011-01-20 | 2015-08-26 | Novan, Inc. | Co-condensation de sol-gel à température contrôlée |
WO2013006613A1 (fr) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Procédés de fabrication de compositions topiques et appareil afférent |
EP2729131B1 (fr) | 2011-07-05 | 2020-04-15 | Novan, Inc. | Compositions topiques |
WO2013029009A1 (fr) | 2011-08-24 | 2013-02-28 | Novan, Inc. | Macromolécules libérant de l'oxyde nitrique ajustables possédant plusieurs structures donneuses d'oxyde nitrique |
WO2013138075A1 (fr) | 2012-03-14 | 2013-09-19 | Novan, Inc. | Compositions pharmaceutiques libérant de l'oxyde nitrique |
US9540471B2 (en) | 2012-07-17 | 2017-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitric oxide-releasing diazeniumdiolated polyvinylpyrrolidone-based polymers, and compositions, medical devices, and uses thereof |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
JP6513667B2 (ja) | 2013-08-08 | 2019-05-15 | ノヴァン,インコーポレイテッド | 局所用組成物およびそれを使用する方法 |
CN106659675B (zh) | 2014-07-11 | 2023-07-04 | 诺万公司 | 局部抗病毒组合物和其使用方法 |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10925689B2 (en) | 2014-07-14 | 2021-02-23 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
CA2919733A1 (fr) | 2014-08-08 | 2016-02-08 | Novan, Inc. | Compositions topiques et methodes d'utilisation desdites compositions |
WO2017151905A1 (fr) | 2016-03-02 | 2017-09-08 | Novan, Inc. | Compositions destinées à traiter l'inflammation et méthodes de traitement associées |
EP3442502A4 (fr) | 2016-04-13 | 2019-11-06 | Novan, Inc. | Compositions, systèmes, kits et méthodes pour traiter une infection |
WO2019169221A1 (fr) | 2018-03-01 | 2019-09-06 | Novan, Inc. | Suppositoires libérant de l'oxyde nitrique et leurs procédés d'utilisation |
-
2006
- 2006-05-30 AU AU2006249323A patent/AU2006249323B2/en active Active
- 2006-05-30 JP JP2008513811A patent/JP5274248B2/ja active Active
- 2006-05-30 EP EP19175594.1A patent/EP3556401A1/fr active Pending
- 2006-05-30 EP EP06771501A patent/EP1888510A4/fr not_active Withdrawn
- 2006-05-30 WO PCT/US2006/020781 patent/WO2006128121A2/fr active Application Filing
- 2006-05-30 EP EP13175233.9A patent/EP2669269B1/fr active Active
- 2006-05-30 CA CA2912259A patent/CA2912259C/fr active Active
- 2006-05-30 ES ES13175233T patent/ES2731298T3/es active Active
- 2006-05-30 US US11/887,041 patent/US20090214618A1/en not_active Abandoned
- 2006-05-30 CA CA2606565A patent/CA2606565C/fr active Active
-
2011
- 2011-06-09 US US13/157,036 patent/US11691995B2/en active Active
- 2011-06-24 US US13/168,597 patent/US8282967B2/en active Active
-
2012
- 2012-09-05 JP JP2012194895A patent/JP2013006859A/ja active Pending
-
2013
- 2013-08-08 JP JP2013164797A patent/JP5753558B2/ja active Active
- 2013-08-30 US US14/015,015 patent/US8962029B2/en active Active
- 2013-08-30 US US14/014,939 patent/US8956658B2/en active Active
-
2014
- 2014-12-17 US US14/573,099 patent/US9403851B2/en active Active
-
2015
- 2015-02-02 US US14/611,574 patent/US9403852B2/en active Active
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4558120A (en) * | 1983-01-07 | 1985-12-10 | The Dow Chemical Company | Dense star polymer |
US4568737A (en) * | 1983-01-07 | 1986-02-04 | The Dow Chemical Company | Dense star polymers and dendrimers |
US4631337A (en) * | 1983-01-07 | 1986-12-23 | The Dow Chemical Company | Hydrolytically-stable dense star polyamine |
US4737550A (en) * | 1983-01-07 | 1988-04-12 | The Dow Chemical Company | Bridged dense star polymers |
US4507466A (en) * | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
US4587329A (en) * | 1984-08-17 | 1986-05-06 | The Dow Chemical Company | Dense star polymers having two dimensional molecular diameter |
US4871779A (en) * | 1985-12-23 | 1989-10-03 | The Dow Chemical Company | Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities |
US4694064A (en) * | 1986-02-28 | 1987-09-15 | The Dow Chemical Company | Rod-shaped dendrimer |
US4713975A (en) * | 1986-05-30 | 1987-12-22 | The Dow Chemical Company | Dense star polymers for calibrating/characterizing sub-micron apertures |
US4857599A (en) * | 1988-02-08 | 1989-08-15 | The Dow Chemical Company | Modified dense star polymers |
US5418301A (en) * | 1992-02-26 | 1995-05-23 | Perstorp Ab | Dendritic macromolecule and process for preparation thereof |
US6180082B1 (en) * | 1997-11-24 | 2001-01-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method to enhance tissue accumulation of radiolabeled compounds |
US6471968B1 (en) * | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
US20030032681A1 (en) * | 2001-05-18 | 2003-02-13 | The Regents Of The University Of Clifornia | Super-hydrophobic fluorine containing aerogels |
US6841166B1 (en) * | 2001-08-21 | 2005-01-11 | The Regents Of The University Of Michigan | Nitric oxide-releasing polymers incorporating diazeniumdiolated silane derivatives |
US20030203915A1 (en) * | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
US20040076582A1 (en) * | 2002-08-30 | 2004-04-22 | Dimatteo Kristian | Agent delivery particle |
US20040254419A1 (en) * | 2003-04-08 | 2004-12-16 | Xingwu Wang | Therapeutic assembly |
US20050037050A1 (en) * | 2003-08-11 | 2005-02-17 | Jan Weber | Medical devices comprising drug-loaded capsules for localized drug delivery |
Cited By (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9427605B2 (en) | 2005-03-24 | 2016-08-30 | Novan, Inc. | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor |
US20090092843A1 (en) * | 2005-05-19 | 2009-04-09 | Joachim Arlt | Process for modifying a silicone rubber surface |
US8962029B2 (en) | 2005-05-27 | 2015-02-24 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9403851B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US11691995B2 (en) | 2005-05-27 | 2023-07-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US9403852B2 (en) | 2005-05-27 | 2016-08-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8956658B2 (en) | 2005-05-27 | 2015-02-17 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US8282967B2 (en) | 2005-05-27 | 2012-10-09 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US20090191284A1 (en) * | 2006-07-26 | 2009-07-30 | Stmicroelectronics S.R.I. | Use of nitroaniline derivatives for the production of nitric oxide |
US8766006B2 (en) | 2006-07-26 | 2014-07-01 | Stmicroelectronics S.R.L. | Use of nitroaniline derivatives for the production of nitric oxide |
US8440849B2 (en) * | 2006-07-26 | 2013-05-14 | Stmicroelectronics S.R.L. | Use of nitroaniline derivatives for the production of nitric oxide |
US20090069884A1 (en) * | 2007-09-06 | 2009-03-12 | Biotronik Vi Patent Ag | Stent having a base body of a biocorrodable alloy |
US8399005B2 (en) * | 2007-10-12 | 2013-03-19 | University Of North Carolina At Chapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
US20100297200A1 (en) * | 2007-10-12 | 2010-11-25 | The University Of North Carolina Atchapel Hill | Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
US20110166536A1 (en) * | 2007-10-30 | 2011-07-07 | Hyde Roderick A | Substrates for nitric oxide releasing devices |
US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US8349262B2 (en) | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
US20090112193A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and devices that utilize photolyzable nitric oxide donors |
US20090112055A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Sleeves configured to facilitate release of nitric oxide |
US11103669B2 (en) | 2009-06-22 | 2021-08-31 | Vero Biotech LLC | Nitric oxide therapies |
US11925764B2 (en) | 2009-06-22 | 2024-03-12 | Vero Biotech Inc. | Nitric oxide therapies |
US20100323036A1 (en) * | 2009-06-22 | 2010-12-23 | Geno Llc | Nitric Oxide Therapies |
WO2010151505A1 (fr) * | 2009-06-22 | 2010-12-29 | Geno Llc | Thérapies par oxyde nitrique |
US9192718B2 (en) | 2009-06-22 | 2015-11-24 | Geno Llc | Nitric oxide therapies |
US8613958B2 (en) * | 2009-06-22 | 2013-12-24 | Geno Llc | Nitric oxide therapies |
US20120136323A1 (en) * | 2009-08-21 | 2012-05-31 | Nathan Stasko | Wound Dressings, Methods of Using the Same and Methods of Forming the Same |
WO2011022680A2 (fr) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Pansements, procédés d'utilisation de ceux-ci et procédés de formation de ceux-ci |
EP4249001A2 (fr) | 2009-08-21 | 2023-09-27 | Novan, Inc. | Gels topiques |
US9526738B2 (en) * | 2009-08-21 | 2016-12-27 | Novan, Inc. | Topical gels and methods of using the same |
US20170056437A1 (en) * | 2009-08-21 | 2017-03-02 | Novan, Inc. | Topical gels and methods of using the same |
US20120134951A1 (en) * | 2009-08-21 | 2012-05-31 | Nathan Stasko | Topical Gels and Methods of Using the Same |
US20180214598A1 (en) * | 2009-08-21 | 2018-08-02 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US11583608B2 (en) * | 2009-08-21 | 2023-02-21 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
WO2011022652A1 (fr) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Gels topiques |
US9737561B2 (en) * | 2009-08-21 | 2017-08-22 | Novan, Inc. | Topical gels and methods of using the same |
US9919072B2 (en) * | 2009-08-21 | 2018-03-20 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US10376538B2 (en) * | 2009-08-21 | 2019-08-13 | Novan, Inc. | Topical gels and methods of using the same |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012082976A1 (fr) | 2010-12-15 | 2012-06-21 | Novan, Inc. | Procédés de diminution de la production de sébum dans la peau |
EP3085354A1 (fr) | 2010-12-15 | 2016-10-26 | Novan, Inc. | Procédés de diminution de la production de sébum de la peau |
CN103379892A (zh) * | 2010-12-15 | 2013-10-30 | 诺万公司 | 减少皮肤中皮脂产生的方法 |
US8937143B2 (en) | 2011-01-20 | 2015-01-20 | Novan, Inc. | Temperature controlled sol-gel co-condensation |
US9267006B2 (en) | 2011-01-20 | 2016-02-23 | Novan, Inc. | Temperature controlled sol-gel co-condensation |
US8981139B2 (en) | 2011-02-28 | 2015-03-17 | The University Of North Carolina At Chapel Hill | Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same |
US9713652B2 (en) | 2011-02-28 | 2017-07-25 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing S-nitrosothiol-modified silica particles and methods of making the same |
WO2012118819A2 (fr) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés |
US9757397B2 (en) | 2011-07-05 | 2017-09-12 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for the same |
US10500220B2 (en) | 2011-07-05 | 2019-12-10 | Novan, Inc. | Topical compositions |
US9289442B2 (en) | 2011-07-05 | 2016-03-22 | Novan, Inc. | Topical compositions |
WO2013006608A1 (fr) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Compositions topiques |
US10265334B2 (en) | 2011-07-05 | 2019-04-23 | Novan, Inc. | Anhydrous compositions |
WO2013029009A1 (fr) | 2011-08-24 | 2013-02-28 | Novan, Inc. | Macromolécules libérant de l'oxyde nitrique ajustables possédant plusieurs structures donneuses d'oxyde nitrique |
US9238038B2 (en) | 2011-08-24 | 2016-01-19 | The University Of North Carolina At Chapel Hill | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures |
US10435357B2 (en) | 2011-08-24 | 2019-10-08 | The University Of North Carolina At Chapel Hill | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures |
US10196349B2 (en) | 2011-08-24 | 2019-02-05 | The University Of North Carolina At Chapel Hill | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures |
US11124476B2 (en) | 2011-08-24 | 2021-09-21 | Novan, Inc. | Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures |
US9901616B2 (en) | 2011-08-31 | 2018-02-27 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
US20130082368A1 (en) * | 2011-09-30 | 2013-04-04 | Samsung Electronics Co., Ltd. | Emi shielded semiconductor package and emi shielded substrate module |
US9669041B2 (en) | 2011-10-27 | 2017-06-06 | Novan, Inc. | Nitric oxide releasing bath compositions and methods of using the same |
WO2013063354A1 (fr) * | 2011-10-27 | 2013-05-02 | Novan, Inc. | Compositions pour bain libérant de l'oxyde nitrique et leurs procédés d'utilisation |
US9042765B2 (en) | 2012-01-16 | 2015-05-26 | Samsung Electronics Co., Ltd. | Image forming apparatus with improved heat transmission |
US10416167B2 (en) | 2012-02-17 | 2019-09-17 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
US10845368B2 (en) | 2012-02-17 | 2020-11-24 | University Of Georgia Research Foundation, Inc. | Nanoparticles for mitochondrial trafficking of agents |
WO2013138075A1 (fr) | 2012-03-14 | 2013-09-19 | Novan, Inc. | Compositions pharmaceutiques libérant de l'oxyde nitrique |
CN104302175A (zh) * | 2012-03-14 | 2015-01-21 | 诺万公司 | 释放一氧化氮的药物组合物 |
AU2013232576B2 (en) * | 2012-03-14 | 2016-09-01 | Novan, Inc. | Nitric oxide releasing pharmaceutical compositions |
US20150024052A1 (en) * | 2012-03-14 | 2015-01-22 | Novan, Inc. | Nitric Oxide Releasing Pharmaceutical Compositions |
US11077194B2 (en) * | 2012-03-14 | 2021-08-03 | Novan, Inc. | Nitric oxide releasing pharmaceutical compositions |
CN104302175B (zh) * | 2012-03-14 | 2017-04-12 | 诺万公司 | 释放一氧化氮的药物组合物 |
US20150125398A1 (en) * | 2012-05-11 | 2015-05-07 | University Of Iowa Research Foundation | Multimodal imaging methods using mesoporous silica nanoparticles |
US20140065200A1 (en) * | 2012-08-28 | 2014-03-06 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing nanorods and their methods of use |
US9187501B2 (en) * | 2012-08-28 | 2015-11-17 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing nanorods and their methods of use |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
US10258564B2 (en) | 2013-02-28 | 2019-04-16 | Novan, Inc. | Topical compositions and methods of using the same |
US11285098B2 (en) | 2013-02-28 | 2022-03-29 | Novan, Inc. | Topical compositions and methods of using the same |
US10226483B2 (en) | 2013-08-08 | 2019-03-12 | Novan, Inc. | Topical compositions and methods of using the same |
US11813284B2 (en) * | 2013-08-08 | 2023-11-14 | Novan, Inc. | Topical compositions and methods of using the same |
CN105979969B (zh) * | 2013-08-08 | 2020-09-11 | 诺万公司 | 局部用组合物和使用所述组合物的方法 |
WO2015021382A3 (fr) * | 2013-08-08 | 2015-11-05 | Novan, Inc. | Compositions topiques et procédés d'utilisation de celles-ci |
CN105979969A (zh) * | 2013-08-08 | 2016-09-28 | 诺万公司 | 局部用组合物和使用所述组合物的方法 |
AU2014305778B2 (en) * | 2013-08-08 | 2019-11-21 | Novan, Inc. | Topical compositions and methods of using the same |
US10206947B2 (en) | 2013-08-08 | 2019-02-19 | Novan, Inc. | Topical compositions and methods of using the same |
US10828323B2 (en) | 2013-08-08 | 2020-11-10 | Novan, Inc. | Topical compositions and methods of using the same |
US20160199295A1 (en) * | 2013-08-08 | 2016-07-14 | Novan, Inc. | Topical compositions and methods of using the same |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
US10736839B2 (en) | 2014-07-11 | 2020-08-11 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
US10322081B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
EP3698775A1 (fr) | 2014-07-11 | 2020-08-26 | Novan Inc. | Compositions antivirales topiques et méthodes d'utilisation |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US11723858B2 (en) | 2014-07-11 | 2023-08-15 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
US11040006B2 (en) | 2014-07-11 | 2021-06-22 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
WO2016007834A1 (fr) | 2014-07-11 | 2016-01-14 | Novan, Inc. | Compositions antivirales topiques et méthodes d'utilisation de celles-ci |
US10925689B2 (en) | 2014-07-14 | 2021-02-23 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
US10849864B2 (en) | 2015-07-28 | 2020-12-01 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
US10582711B2 (en) * | 2015-09-25 | 2020-03-10 | Leader Optronics Technology Co., Ltd. | Method for imparting to an article or product antimicrobial activity and the article or product having the antimicrobial activity |
US11420986B2 (en) | 2015-11-02 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Functionalized mesoporous silica via an aminosilane surfactant ion exchange reaction: controlled scaffold design and nitric oxide release |
WO2017079268A1 (fr) * | 2015-11-02 | 2017-05-11 | University Of North Carolina- Chapel Hill | Silice mésoporeuse fonctionnalisée par une réaction d'échange d'ions tensioactifs de type aminosilane : conception régulée d'échafaudage et libération d'oxyde nitrique |
US10912743B2 (en) | 2016-03-02 | 2021-02-09 | Novan, Inc. | Compositions for treating inflammation and methods of treating the same |
US11166980B2 (en) | 2016-04-13 | 2021-11-09 | Novan, Inc. | Compositions, systems, kits, and methods for treating an infection |
WO2018067838A1 (fr) * | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | Polyesters hyperramifiés médiés par un s-nitrosothiol |
CN109937234A (zh) * | 2016-10-07 | 2019-06-25 | 北卡罗来纳大学教堂山分校 | S-亚硝基硫醇介导的超支化聚酯 |
US11186681B2 (en) * | 2016-10-07 | 2021-11-30 | The University Of North Carolina At Chapel Hill | S-Nitrosothiol-mediated hyperbranched polyesters |
US11072668B2 (en) | 2017-01-03 | 2021-07-27 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11697693B2 (en) | 2017-01-03 | 2023-07-11 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11723914B2 (en) | 2017-03-28 | 2023-08-15 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
CN110461338A (zh) * | 2017-03-28 | 2019-11-15 | 北卡罗来纳大学查佩尔希尔分校 | 作为可生物降解抗菌支架的释放一氧化氮的聚氨基糖苷类和其制备方法 |
US11534382B2 (en) | 2017-06-19 | 2022-12-27 | Novan, Inc. | Topical compositions and methods of using the same |
US20210380420A1 (en) * | 2017-08-01 | 2021-12-09 | University Of Georgia Research Foundation, Inc. | Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof |
US11897775B2 (en) * | 2017-08-01 | 2024-02-13 | University Of Georgia Research Foundation, Inc. | Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof |
US11117808B2 (en) * | 2017-08-01 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof |
US20190039910A1 (en) * | 2017-08-01 | 2019-02-07 | University Of Georgia Research Foundation, Inc. | Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof |
US11331019B2 (en) | 2017-08-07 | 2022-05-17 | The Research Foundation For The State University Of New York | Nanoparticle sensor having a nanofibrous membrane scaffold |
US11285171B2 (en) * | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
US11672818B2 (en) | 2018-03-06 | 2023-06-13 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
US11026965B2 (en) | 2018-03-06 | 2021-06-08 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
WO2019201195A1 (fr) | 2018-04-16 | 2019-10-24 | 上海岸阔医药科技有限公司 | Méthode pour prévenir ou traiter les effets secondaires d'une cancérothérapie |
CN108414655A (zh) * | 2018-05-28 | 2018-08-17 | 陕西师范大学 | 一种磁性超支化聚酰胺-胺及在有机磷农药残留检测中的应用 |
US11421044B2 (en) | 2018-12-28 | 2022-08-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
WO2020180705A1 (fr) * | 2019-03-01 | 2020-09-10 | The University Of North Carolina At Chapel Hill | Polymères étendus libérant de l'oxyde nitrique par l'intermédiaire de nanoparticules de silice mésoporeuse fonctionnalisées |
CN113507924A (zh) * | 2019-03-01 | 2021-10-15 | 北卡罗来纳大学教堂山分校 | 通过官能化介孔二氧化硅纳米颗粒的一氧化氮延长释放型聚合物 |
CN114630661A (zh) * | 2019-11-05 | 2022-06-14 | 佐治亚大学研究基金会股份有限公司 | 功能改性的美登木素生物碱及其组合物和使用方法 |
WO2022015840A3 (fr) * | 2020-07-16 | 2022-02-10 | University Of Georgia Research Foundation, Inc. | Substrats polymères antimicrobiens de qualité médicale présentant des propriétés antifongiques et antibactériennes |
Also Published As
Publication number | Publication date |
---|---|
CA2606565C (fr) | 2016-05-10 |
US9403852B2 (en) | 2016-08-02 |
CA2912259A1 (fr) | 2006-11-30 |
JP2013006859A (ja) | 2013-01-10 |
EP2669269A3 (fr) | 2014-03-05 |
US8282967B2 (en) | 2012-10-09 |
JP2013256512A (ja) | 2013-12-26 |
JP5274248B2 (ja) | 2013-08-28 |
ES2731298T3 (es) | 2019-11-14 |
US20120021055A1 (en) | 2012-01-26 |
US20140058124A1 (en) | 2014-02-27 |
CA2606565A1 (fr) | 2006-11-30 |
EP1888510A4 (fr) | 2013-01-16 |
JP5753558B2 (ja) | 2015-07-22 |
EP2669269B1 (fr) | 2019-05-22 |
WO2006128121A3 (fr) | 2007-05-03 |
US20160060279A1 (en) | 2016-03-03 |
US20140005426A1 (en) | 2014-01-02 |
US11691995B2 (en) | 2023-07-04 |
US8962029B2 (en) | 2015-02-24 |
EP2669269A2 (fr) | 2013-12-04 |
JP2008545714A (ja) | 2008-12-18 |
US9403851B2 (en) | 2016-08-02 |
CA2912259C (fr) | 2020-04-28 |
US20120034169A1 (en) | 2012-02-09 |
US20150182543A1 (en) | 2015-07-02 |
WO2006128121A2 (fr) | 2006-11-30 |
US8956658B2 (en) | 2015-02-17 |
AU2006249323A1 (en) | 2006-11-30 |
AU2006249323B2 (en) | 2012-08-30 |
EP3556401A1 (fr) | 2019-10-23 |
EP1888510A2 (fr) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9403852B2 (en) | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | |
US9187501B2 (en) | Nitric oxide-releasing nanorods and their methods of use | |
AU2008218275B2 (en) | Bridged polycyclic compound based compositions for the inhibition and amelioration of disease | |
US20080226583A1 (en) | Therapeutic polyesters and polyamides | |
Knežević et al. | Silicon-based nanotheranostics | |
US20090054528A1 (en) | Bridged polycyclic compound based compositions for coating oral surfaces in pets | |
AU2014221249B2 (en) | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | |
AU2012211421B2 (en) | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications | |
Amjad et al. | Nano particles: An emerging tool in biomedicine | |
Barui et al. | Medicinal applications of metal nanoparticles | |
Shringirishi et al. | Gold nanoparticles: Promising and potential nanomaterial | |
RU2752177C1 (ru) | Векторизованные водосовместимые полимерные мицеллярные частицы для доставки биологически активных веществ через гематоэнцефалический барьер | |
Singh et al. | Ligand-based surface engineering of nanomaterials: Trends, challenges, and biomedical perspectives | |
KR20160113496A (ko) | 무기 고분자 하이브리드 콜로이드 화합물 및 그의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERISTY OF NORTH CAROLINA AT CHAPEL HILL, THE, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHOENFISCH, MARK H.;SHIN, JAE HO;STASKO, NATHAN;REEL/FRAME:019944/0902 Effective date: 20071001 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF NORTH CAROLINA CHAPEL HIL;REEL/FRAME:022937/0652 Effective date: 20090709 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, N Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF ASSIGNEE NAME RECORDED INCORRECTLY AS THE "UNIVERISTY" OF NORTH CAROLINA AT CHAPEL HILL PREVIOUSLY RECORDED ON REEL 019944 FRAME 0902. ASSIGNOR(S) HEREBY CONFIRMS THE SPELLING OF ASSIGNEE NAME IS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL;ASSIGNORS:SCHOENFISCH, MARK H.;SHIN, JAE HO;STASKO, NATHAN;REEL/FRAME:027011/0316 Effective date: 20071001 |